Method for the enzyme-catalysed hydrolysis of polyacrylic acid esters, and esterases used therefor

ABSTRACT

The invention relates to a method for the enzyme-catalysed hydrolysis of polyacrylic acid esters. According to said method, at least one polyacrylic acid ester is provided and incubated with at least one enzyme selected from enzymes (EC 3.1) acting on ester bindings, until the ester groups contained in the polyacrylic acid ester are partially or fully hydrolytically split, and optionally the modified polymer obtained thereby is isolated. The invention also relates to the enzymes used and mutants thereof, nucleic acids coding for the enzymes, vectors comprising the nucleic acids, micro-organisms comprising the vectors, and the use of the enzymes, the vectors or the micro-organisms for carrying out a method for the enzyme-catalysed hydrolysis of polyacrylic acid esters. The present application also relates to polymer reaction products that can be obtained by the method, and methods for producing esterases.

The present invention relates to a method for the enzyme-catalyzed hydrolysis of polyacrylic acid esters, the enzymes used and mutants thereof, the enzymes encoding nucleic acids, the nucleic acids comprising vectors, the vectors comprising microorganisms, the use of the enzymes, the vectors or the microorganisms for carrying out a method for the enzyme-catalyzed hydrolysis of polyacrylic acid esters. The present application relates furthermore to polymeric reaction products obtainable by the method and methods for the production of esterases.

PRIOR ART

Polyacrylic acid esters (polyacrylates) are compounds with numerous uses. For polyacrylates from homopolymers the possible uses are rather limited, whereas in the case of polyacrylates from copolymers it is possible, by selecting the comonomers to be used (for example methylacrylates, styrene, acrylonitrile, vinyl acetate, vinyl chloride, vinylidene chloride and butadiene) to exert an influence on the properties of the polyacrylates in various ways and therefore provide access to the most varied possible uses.

Chemical methods for cleavage of polyacrylic acid esters, for example alkaline saponification (U.S. Pat. No. 3,926,891), are known by a person skilled in the art. US patent application 2004/0082023 A1 describes a method of enzymatic esterification of polymers bearing carboxyl groups using enzymes such as lipases or esterases. Polyacrylates are not named explicitly as possible polymers, nor is there any mention of the suitability of the method for the enzyme-catalyzed ester cleavage of polyacrylate esters.

O'Sullivan and Birkinshaw described an attempt to hydrolyze poly-(n-butylcyanoacrylate) nanoparticles by esterase from pig's liver (O'Sullivan, Birkinshaw, Polymer Degradation and Stability 78: 7-45, 2002). Belucci et al. reported on the careful removal of acrylic resin coatings from the surface of paintings using lipase (Belluci et al., Study in Conservation 44: 278-281, 1999).

A large number of esterases are known by a person skilled in the art. Esterases of Burkholderia gladioli are described for example in Peterson et al., J. Biotechnol. 89:11-25 (2001), Valinger et al., J. Biotechnol. 129:98-108 (2007), Ivancic et al., J. Biotechnol. 129:109-122 (2007) and Reiter et al., Appl. Microbiol. Biotechnol. 54:778-785 (2000). Suitability of these esterases for the cleavage of polymer substrates has not been described before.

The problem on which the present invention is based therefore consists of providing a method for the enzyme-catalyzed hydrolysis of polyacrylic acid esters and suitable enzymes therefor, their nucleic acids, the nucleic acid-containing vectors or the vector-containing microorganisms, and reaction products obtainable by the method.

BRIEF DESCRIPTION OF THE INVENTION

The aforementioned problem was solved, surprisingly, by the use of esterases, in particular enzymes selected from carboxyl esterases, triacyl lipases and cutinases, in a method for the enzyme-catalyzed hydrolysis of polyacrylic acid esters and by the provision of corresponding esterases and of the nucleic acids encoding them.

DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a structural model of EstB. Two loops, which were identified as covering the access to the catalytically active center, are highlighted and marked with arrows. The amino acid residue, highlighted and also indicated with an arrow, represents the nucleophilic serine of the active center.

FIG. 2 shows a structural model of EstC according to SEQ ID NO:2, with phenylalanine 138 replaced with alanine (Phe138Ala; corresponding to the mutant 1K22 in FIG. 5). The backbone of the polypeptide chain is shown. The amino acid phenylalanine in position 138, marked with an arrow, is represented as a space-filling model, the amino acids given in the illustration below Phe138 as space-filling model correspond to the amino acids Ser112, Asp242 and His 275 belonging to the catalytically active center.

FIG. 3 shows a structural model of EstC according to SEQ ID NO:2, with leucine 193 replaced with alanine (Leu193Ala; corresponding to the mutant 2K20 in FIG. 5). The backbone of the polypeptide chain is shown. The amino acid leucine in position 193, marked with an arrow, is represented as a space-filling model, the amino acids given in the illustration above Leu193 as space-filling model correspond to the amino acids Ser112, Asp242 and His275 belonging to the catalytically active center.

FIG. 4 shows a structural model of EstC according to SEQ ID NO:2, with phenylalanine 138 replaced with alanine, leucine 193 with alanine, and threonine 188 with serine (Phe138Ala, Leu193Ala, Thr188Ser; corresponding to mutant B48 in FIG. 5). The backbone of the polypeptide chain is shown. The amino acids Phe138, Thr188 and Leu193 represented as a space-filling model are marked with an arrow. The other amino acids given as a space-filling model correspond to the amino acids Ser112, Asp242 and His275 belonging to the catalytically active center.

FIG. 5 gives an overview of active mutants and activities. The results were obtained by pH-shift assays with esterase C (FIG. 5 a) and esterase B (FIG. 5 b) and various functional mutants thereof. The following symbols were used for the activity: +++=very active, ++=active, +=weakly active, ∘=not active

EstB and mutants thereof were not tested for α-naphthyl acetate in obtaining these data, however, the inventors have data available showing that all three EstB variants have activity with respect to this substrate.

FIG. 6 shows the enzyme-catalyzed ester cleavage of PBA after adding raw lysate of the esterase-producing strain NJ70 (equivalent to 1000 units of EstB_NJ70) in comparison with chemical ester cleavage after adding raw lysate after denaturation.

FIG. 7 shows autotitrations of EstB-esterases (wild type and mutants) with the substrate PBA. A possible inhibitory action of Sokalan (=polyacrylic acid) was investigated.

FIG. 8 shows the enzyme-catalyzed ester cleavage as a function of pH. All measurements were performed with 1000 units of EstB_NJ70 (determined with p-NPB) and 750 μl PBA.

FIG. 9 shows the temperature dependence of enzyme-catalyzed ester cleavage. All autotitrations were performed with 1000 units of EstB_NJ70 (determined with p-NPB) and 750 μl PBA.

FIG. 10 shows the course of the reaction of ester cleavage by EstB_NJ70 in solution or immobilized EstB_NJ70. The results are shown of autotitrations with 4.66 mmol PBA of EstB_NJ70 either nonimmobilized or immobilized on Eupergit.

FIG. 11 shows the cleavage of polyacrylic acid methyl esters of different chains length, with denatured enzyme used as control.

DETAILED DESCRIPTION OF THE INVENTION I. Explanations of General Terms

Within the scope of the present invention, unless specified otherwise, the term “esterases” generally denotes enzymes that catalyze the hydrolysis of ester bonds.

“Enzymes acting on ester bonds” means enzymes of class 3.1 according to the EC classification. “Carboxylic acid ester hydrolases” means enzymes of class 3.1.1 according to the EC classification. “Carboxyl esterases”, “triacylglycerol lipases” or “cutinases” mean enzymes of EC classes 3.1.1.1, 3.1.1.3 and/or 3.1.1.74.

“Esterases of family VIII” are covered by the definition given in Petersen et al., J Biotechnol 89:11-25 (2001) and in Arpigny and Jaeger, Biochem J 343:177-183 (1999). Esterases of family VIII are therefore characterized by an active site that has a Ser-X-X-Lys motif (where X stands for any amino acid) and therefore have similarity with the active site of β-lactamases of class C, it being possible for the esterase activity to be detected if necessary by one of the esterase activity assays described in Petersen et al. (ibid.).

Within the scope of the invention, type C esterases are to be understood as enzymes that have at least 50% identity at the amino acid level with EstC from Burkholderia gladioli (Reiter et al., Appl Microbiol Biotechnol 54:778-785 (2000) according to SEQ ID NO:2, and moreover at least 20% identity at the amino acid level with the hydroxynitrile lyase from Hevea brasiliensis (Hasslacher M et al., J Biol Chem 271:5884-5891 (1996), GenBank accession No. AAC49184), SEQ ID NO:58, and/or the hydroxynitrile lyase from Manihot esculenta (Hughes et al., Arch Biochem Biophys 311:96-502 (1994), Swiss-Prot accession No. P52705), SEQ ID NO:59.

Within the scope of the present invention, an “enzyme-catalyzed hydrolysis” of a polyacrylic acid ester also comprises reactions that include a partial autolysis. In “partial autolysis” a proportion of 0-90 mol. %, 0-50 mol. %, 0-25 mol. %, 0-20 mol. %, in particular 0-15 mol. %, 0-10 mol. %, 0-5 mol. % or 0-1 mol. % of the ester groups is cleaved autolytically.

Halogen means fluorine, chlorine, bromine or iodine.

A loop or a loop structure means a segment of successive amino acids in the primary structure, which forms a loop-shaped structural element in the tertiary structure of the protein.

Hydrolysis of polyacrylic acid esters or hydrolysis activity against polyacrylic acid esters means the incomplete or complete hydrolysis of the ester bonds of the polyacrylic acid esters.

The statement “about” means that the value given optionally has a deviation of up to 25% above or below, in particular up to 10% above or below, or up to 5% above or below.

Average molecular weight means, unless further specified, the weight-average molecular weight.

An alternating copolymer is to be understood as a copolymer consisting of two monomers A and B, the monomers being in a strictly alternating sequence (AB)_(n). A random copolymer means a copolymer in which the monomers (e.g. A and B) are incorporated randomly in the macromolecule that forms during copolymerization, i.e. in a purely random order. A gradient copolymer is a copolymer in which there is a gradient of the distribution of the monomer building blocks (e.g. the building blocks A and B) along the chains of the copolymers. A block polymer is a polymer whose molecules consist of linearly linked blocks. A block is to be understood as a segment of a polymer molecule that comprises several identical repeat units and has at least one constitutional or configurative feature that differs from those of the adjoining segments (blocks). The blocks are joined together directly or via constitutional units, which are not part of the blocks. Block copolymers are block polymers that consist of more than one kind of monomer and can be described e.g. for block copolymers constructed from two kinds of monomers A and B by the general formula -A_(k)-B_(l)-A_(m)-B_(n)-, where k, l, m and n stand for the number of repeat units in the individual blocks. Graft copolymers are polymers produced according to the method of graft copolymerization, with their structure having the characteristic that they possess, on their main chain, side chains that are of a length such that they could already be regarded as polymers. The main and side chains can be chemically identical or different.

Alcohol derivatives are to be understood as molecules derived from alcohols, for example alcohols in which one or more hydroxyl groups are replaced with other functional groups, for example amino groups or sulfhydryl groups.

A “partial” ester cleavage occurs when, after carrying out the method according to the invention, the ester groups originally present (i.e. basically cleavable) have not been cleaved. For example, a partial cleavage can relate to values from 0.1 to 99.9% of the ester groups originally contained, e.g. at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20%, or at most 99, 98, 97, 96, 95, 94, 93, 92, 91, 90, 89, 88, 87, 86, 85, 84, 83, 82, 81, 80%, for example 1 to 95, 2 to 90, 3 to 85, 4 to 80, 5 to 75, 6 to 70, 7 to 65, 8 to 60, 9 to 55, 10 to 50, 11 to 45, 12 to 40, 13 to 35, 14 to 30, 15 to 25 or 16 to 20%. The cleavage can take place regio-nonspecifically, i.e. essentially randomly distributed in the polymer molecule, or regio-specifically, i.e. nonrandomly distributed, predominantly in one or more specific regions of the molecule, e.g. in one or more terminal regions of the molecule.

A “mutant of an esterase according to SEQ ID NO: X” or a “mutant derived from SEQ ID NO:X” means that, starting from this SEQ ID NO:X, this mutant is produced by undertaking at least one mutation described herein or at least one combination of mutations described herein.

The following abbreviations are used, among others:

DG: 2,4-dimethylglutaric acid-dimethyl ester DB: 2,4-dimethylglutaric acid-dibutyl ester PMA: polymethylacrylate PBA: polybutylacrylate α-N: α-naphthyl acetate p-NPA: para-nitrophenylacetate p-NPB: para-nitrophenylbutyrate

II. Special Objects of the Invention

A first object of the invention relates to methods for the enzyme-catalyzed hydrolysis of polyacrylic acid esters, with at least one polyacrylic acid ester being prepared, and the at least one polyacrylic acid ester is incubated with at least one enzyme, which is selected from enzymes acting on ester bonds (EC 3.1), until the ester groups contained in the polyacrylic acid ester have been hydrolytically cleaved partially or completely, and optionally the resultant modified polymer is isolated. In this method, the polyacrylic acid ester can be a homopolymer or a copolymer from two or more different monomers.

According to further embodiments, the enzyme is selected from carboxylic acid ester hydrolases (EC 3.1.1). According to especially preferred embodiments the carboxylic acid ester hydrolases are selected from carboxyl esterases (E.C 3.1.1.1), triacylglycerol lipases (EC 3.1.1.3) and cutinases (EC 3.1.1.74).

According to further embodiments the polyacrylic acid ester is a homopolymer or a copolymer. Examples of copolymers are alternating copolymers, statistical copolymers, gradient copolymers, block copolymers or graft copolymers. The monomers of the copolymers can be for example all the monomers disclosed here.

According to a preferred embodiment of the method, the polymer comprises monomer building blocks of general formula I

R¹R²C═CR³—COOR⁴  (I),

in which R¹, R² and R³ may be identical or different and are selected from H, a linear C₁-C₂₀ hydrocarbyl residue and a branched C₃-C₂₀ hydrocarbyl residue, and R⁴ is selected from H, a linear C₁-C₂₀ or C₁-C₆ hydrocarbyl residue, a branched C₃-C₂₀ or C₃-C₆ hydrocarbyl residue and a cyclic C₃-C₂₀ or C₅-C₇ hydrocarbyl residue, the hydrocarbyl residue optionally being substituted with one or more identical or different groups, which are selected from hydroxyl, amino, epoxide groups and halogen atoms, and in the polymer, in at least one monomer building block of formula I, R⁴ is selected from a linear C₁-C₂₀ or C₁-C₆ hydrocarbyl residue, a branched C₃-C₂₀ or C₃-C₆ hydrocarbyl residue and a cyclic C₃-C₂₀ or C₅-C₇ hydrocarbyl residue, the hydrocarbyl residue optionally being substituted with one or more identical or different groups, which are selected from hydroxyl, amino, epoxide, thiol groups and halogen atoms.

Linear C₁-C₂₀ hydrocarbyl residues comprise methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonodecyl and eicosyl residues. Branched C₃-C₂₀ hydrocarbyl residues comprise for example isopropyl, isobutyl, isopentyl, 2,2-dimethylpropyl, isohexyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, isoheptyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2,3-trimethylbutyl, isooctyl, 3-methylheptyl, 4-methylheptyl, 2,2-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2,3-trimethylpentyl, 2,2,4-trimethylpentyl, 2,2,5-trimethylpentyl and isononyl residues. Examples of C₃-C₂₀ cycloalkyl residues are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotridecyl, cyclotetradecyl, cyclopentadecyl, cyclohexadecyl, cycloheptadecyl, cyclooctadecyl, cyclononadecyl and cycloeicosyl residues. Nonlimiting examples of substituted hydroxycarbyl residues are hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, hydroxyheptyl, hydroxyoctyl, hydroxynonyl and hydroxydecyl residues. The polymer of general formula (I) can thus, if several hydroxyl groups are present, be a polyol. According to further, nonlimiting examples, the hydroxycarbyl residues are selected from carbohydrates, thus in particular polyhydroxyaldehydes and polyhydroxyketones, which can be in the form of monomers, oligomers or polymers. Identical or different monomers can be present in one polyacrylic acid ester, and oligomers or polymers can comprise identical or different monomers. Carbohydrates are known by a person skilled in the art, and nonlimiting examples of polyhydroxyaldehydes include threose, ribose, arabinose, xylose, lyxose; nonlimiting examples of polyhydroxyketones include dihydroxyacetone, erythrulose, ribulose, xylulose, fructose, sorbose, mannoheptulose.

According to a further embodiment, the method according to the invention is characterized in that the polyacrylic acid ester contains, additionally to the monomers of formula I, at least one further monomer component different therefrom, in a molar proportion from 0 to 15 mol. %, which preferably is selected from N-vinylformamide, methacrylic acid, methacrylic acid ester, itaconic acid, itaconic acid ester, vinylphosphonic acid, vinylsulfonic acid, vinyl alcohol, N-vinylimidazole, N-vinylformamide, styrene, maleic acid, maleic acid ester, ethylene, propylene acrylamide and substituted acrylamides, where the substituent is selected from a linear C₁-C₂₀ or C₁-C₆ hydrocarbyl residue, a branched C₃-C₂₀ or C₃-C₆ hydrocarbyl residue and a cyclic C₃-C₂₀ or C₅-C₇ hydrocarbyl residue, the hydrocarbyl residue optionally being substituted with one or more identical or different groups, which are selected from hydroxyl, amino, epoxide, thiol groups and halogen atoms.

In one embodiment of the method, the acrylic acid groups of the polyacrylic acid esters are completely or substantially completely esterified prior to the hydrolysis.

In the methods according to the invention the average molecular weight of the polyacrylic acid ester is up to about 3 000 000, for example from about 1000 up to about 3 000 000, in particular up to about 200 000, 150 000, 100 000 or 50 000. The polyacrylic acid ester is preferably selected from polyacrylic acid methyl esters with an average molecular weight from about 20 000 to about 3 000 000, in particular about 30 000 to about 50 000, in particular about 40 000, and polyacrylic acid butyl esters with an average molecular weight from about 20 000 to about 3 000 000, in particular about 90 000 to about 110 000, in particular about 99 000.

In further embodiments of the method according to the invention the incubation takes place at a pH from 5 to 14, preferably 7 to 12, 8.5 to 11.5, in particular at a pH from 9 to 11 or at a pH from 7 to 9.

According to further embodiments of the method according to the invention, the enzyme is in a solution, in particular in an aqueous, organic or aqueous-organic, organic-aqueous or organic solution. Within the scope of the present invention, organic-aqueous or aqueous-organic solutions comprise not only homogeneous solutions of fully miscible components (for example water and organic solvent), but also two-phase systems or multiphase systems, for example water-in-oil emulsions, oil-in-water emulsions, water-in-oil-in-water emulsions, etc. The enzyme is then preferably completely or mainly in the aqueous phase, and the polyacrylic acid ester preferably completely or mainly in the organic phase. According to special embodiments the volume ratio of aqueous to organic component or of aqueous to organic phase is about 75:25 to 25:75, for example about 60:40 to about 40:60, about 55:45 to about 45:55, in particular about 50:50.

According to special embodiments the enzyme is present in nonimmobilized form.

According to a further embodiment of the method according to the invention, the enzyme is present in immobilized form. Examples of immobilized enzymes are enzymes bound covalently or noncovalently on microspheres or flat-shaped supports. Suitable methods for immobilization of enzymes are known by a person skilled in the art and are described for example in S. Fukui, A. Tanaka, “Enzymes”, in: Ullmann's Encyclopedia of Industrial Chemistry, 5th edition, Wiley-VCH, New York, Berlin, 1985; J. E. Prenosil, O. M. Kut, I. J. Dunn, E. Heinzle, “Immobilized Biocatalysts”, in: Ullmann's Encyclopedia of Industrial Chemistry, 6th edition, VCH, New York, Berlin, 2003, p. 503-554; J. F. Kennedy, J. M. S. Cabral, in: H. J. Rehm, G. Reed (Eds.), Biotechnology: A comprehensive treatise in 8 volumes; Vol. 7a, p. 349-404; VCH, Weinheim, 1987. Noncovalent binding of the enzyme can for example be achieved by labeling the enzyme with biotin and immobilization on a support provided with avidin or streptavidin, labeling of the enzyme by incorporating histidine tags in its amino acid sequence and immobilization on a support provided with nickel chelate, immobilization of the enzyme by antibodies directed against the enzyme (the binding epitopes preferably being selected so that the binding between antibody and binding epitope does not, or substantially does not, impair the access of substrate molecules to the active site), preparation of fusion proteins from the enzyme and a foreign protein and immobilization of the protein by antibodies directed against the foreign protein. By analogy with the above account, enzymes present in immobilized form can be a constituent of a two-phase system or multiphase system. For example, an enzyme immobilized on a solid support (for example a microsphere) can be regarded as solid phase, which is present within a two-phase system in a liquid phase (water or organic solvent), or the enzyme immobilized on a solid support can be present as solid phase in an already two-phase or multiphase liquid system (for example a water-in-oil emulsion or an oil-in-water emulsion).

According to a further embodiment, the method is carried out in a bioreactor.

In a further embodiment of the method according to the invention the enzyme is an esterase, which is selected from esterases of family VIII, type C esterases, a cutinase according to SEQ ID NO:5 or cutinases derived therefrom, and a triacylglycerol lipase according to SEQ ID NO:6 or triacylglycerol lipases derived therefrom. In a special embodiment the esterase of type VIII is the esterase B from Burkholderia gladioli (ATCC 10248) according to SEQ ID NO:1, in another special embodiment the type C esterase is the esterase C from Burkholderia gladioli (ATCC 10248) according to SEQ ID NO:2. The invention also relates to functional mutants of the aforesaid esterases.

According to further embodiments of the method according to the invention the esterase is a functional mutant of an esterase according to SEQ ID NO:1 or SEQ ID NO:2 with comparable or increased activity with respect to the hydrolysis of polyacrylic acid esters relative to SEQ ID NO:1 or SEQ ID NO:2, and/or a functional mutant of an esterase according to SEQ ID NO:1 or SEQ ID NO:2 with increased stability relative to SEQ ID NO:1 or SEQ ID NO:2, for example against the influence of organic solvents or with respect to denaturation by elevated temperatures.

According to further embodiments of the method according to the invention the mutant displays, in comparison with an esterase according to SEQ ID NO:1 or SEQ ID NO:2, an increased hydrolysis activity with respect to polyacrylic acid methyl esters and/or polyacrylic acid butyl esters. The hydrolysis activity can for example be determined quantitatively by a titration assay, in which ester cleavage takes place in solution and the decrease in pH caused by the acid groups that are released is compensated by adding NaOH (or another pH correctant). Increased hydrolysis activity occurs for example when the mutant brings about, in comparison with the corresponding esterase according to SEQ ID NO:1 or SEQ ID NO:2, a quicker establishment of reaction equilibrium (i.e. the same amount of NaOH has to be added in a shorter time) and/or displaces the equilibrium towards more complete hydrolysis (i.e. more NaOH must be added). The hydrolysis activity can furthermore be determined semi-quantitatively in a pH-shift assay by incubation of the enzyme mutant or of a microorganism producing the enzyme mutant with a substrate containing polyacrylic acid ester, which can be supplied for example in an agar medium or on a filter membrane, and determination of the drop in pH due to acid groups being released, by color change of a pH indicator that is also present. There is increased hydrolysis activity if the mutant, in comparison with the corresponding esterase according to SEQ ID NO:1 or SEQ ID NO:2, brings about a quicker change to low pH values or a more intense change (larger color change halos around enzyme-containing sites) to lower pH values.

According to further embodiments, the method according to the invention is characterized in that

-   (a) the esterase is a mutant of an esterase according to SEQ ID     NO:1, which has at least one mutation, e.g. 1, 2, 3, 4, 5, 6 or 7     mutations, in one or more of the amino acid residues Ser17, Gly132,     Trp134, Arg155, Glu251, Ala311 and Glu316; or -   (b) the esterase is a mutant of an esterase according to SEQ ID     NO:2, which has at least one mutation, e.g. 1, 2, 3, 4 or 5     mutations, in one or more of the amino acid residues Phe138, Val150,     Leu160, Thr188 and Leu193.

In further embodiments the method according to the invention is characterized in that the esterase is derived from SEQ ID NO:1 and comprises

-   a) at least one, e.g. 1, 2, 3, 4 or 5 mutations, of the mutations     Ser17Leu, Gly132Ser, Glu251Gly, Ala31Val and Glu316Lys and/or -   b) at least one, e.g. 1, 2, 3, 4, 5, 6 or 7 mutations, of the     mutations Pro8Leu, Gly132Ser, Trp134Arg, Arg155Cys, Glu251Gly,     Ala311Val and Glu316Lys.

In especially preferred embodiments the method according to the invention is characterized in that the esterase is derived from SEQ ID NO:1 and comprises

-   (a) the mutations Ser17Leu, Gly132Ser, Glu251Gly, Ala31Val and     Glu316Lys; or -   (b) the mutations Pro8Leu, Gly132Ser, Trp134Arg, Arg155Cys,     Glu251Gly, Ala311Val and Glu316Lys.

Esterases according to SEQ ID NO:3 or SEQ ID NO:4 represent special embodiments.

In further special embodiments the method according to the invention is characterized in that the esterase is derived from SEQ ID NO:2 and comprises one of the following mutations or combinations of mutations (i.e. one of the single or multiple mutations listed below):

-   -   (a) Phe138Ala     -   (b) Phe138Ala, Thr188Ser     -   (c) Phe138Ala, Leu160Ala, Thr188Ser     -   (d) Leu193Ala     -   (e) Leu193Ala, Phe138Ala, Thr188Ser, Val150Ala     -   (f) Leu193Ala, Phe138Ala, Thr188Ser     -   (g) Leu193Ala, Phe138Ala, Thr188Ser, Leu160Ala, Val150Ala     -   (h) Val150Ala     -   (i) Val150Ala, Thr188Ser     -   (j) Leu193Ala, Phe138Val     -   (k) Leu193Ala, Phe138Val, Thr188Ser, Val150Ala     -   (l) Leu193Ala, Thr188Ser     -   (m) Leu193Ala, Phe138Val, Thr188Ser     -   (n) Leu193Ala, Phe138Val, Thr188Ser, Leu160Ala     -   (o) Phe138Val, Val150Ala, Thr188Ser     -   (p) Phe138Val     -   (q) Phe138Val, Thr188Ser

According to further embodiments of the method according to the invention the esterase is a deletion mutant of an esterase of type VIII or of a type C esterase. Preferably the esterase has a loop shortening. Suitable regions for a loop shortening in the case of an esterase according to SEQ ID NO:1 (EstB of B. gladioli) are for example the regions Glu246 to Arg258 and Gly312 to 323. Loop shortenings can be effected by removing one or more amino acids, and in the case when several amino acids are removed, in their turn one or more adjacent or nonadjacent amino acids in SEQ ID NO:1 can be removed. Deletion mutants of the amino acid sequences given under SEQ ID NO:37 and SEQ ID NO:38 represent special embodiments.

Another object of the invention relates to the previously mentioned functional esterase mutants.

Another object of the invention relates to nucleic acids

-   -   a) which code for functional esterase mutants, or     -   b) which represent nucleic acids complementary to a), and/or     -   c) nucleic acids hybridizing with a nucleic acid according to a)         or b) under stringent conditions, in particular those nucleic         acids that have a sequence identity of at least 80% and code for         a mutant of an esterase of family VIII or a type C esterase         mutant, which hydrolyzes polyacrylic acid esters.

Another object of the invention relates to a vector, comprising one of the aforementioned nucleic acids. According to a special embodiment the nucleic acid is linked operatively with a promoter.

Another object of the invention relates to a microorganism, comprising at least one of the aforementioned vectors.

Another object of the invention relates to a method of production of one of the aforementioned functional esterase mutants, in which

-   -   a) a host organism capable of expressing the esterase, for         example the aforementioned microorganism, which contains at         least one of the aforementioned vectors, is cultivated     -   b) optionally the expression of the esterase is induced, and     -   c) optionally the esterase is isolated from the host organism         and/or the culture medium.

Another object of the invention relates to the use of one of the aforementioned esterases, one of the aforementioned vectors, or one of the aforementioned microorganisms for carrying out one of the aforementioned methods of ester hydrolysis, or for the corresponding transesterification of said polyacrylic acid esters.

Another object of the invention relates to a polymeric reaction product, which is obtainable by one of the aforementioned methods.

III. Further Information Regarding Carrying Out of the Invention 1. Method for the Enzyme-Catalyzed Hydrolysis of Polyacrylic Acid Esters

The method according to the invention relates to an enzyme-catalyzed hydrolysis of polyacrylic acid esters, which in this text is also called enzymatic ester cleavage (or briefly: ester cleavage).

Within the scope of the method according to the invention, the preparation of at least one polyacrylic acid ester and its incubation with at least one esterase are envisaged. Preparation preferably takes place in a solution, which can be an aqueous solution, an organic solution (comprising one or more organic solvents) or aqueous-organic solution (with the organic solvent component comprising one or more organic solvents). The organic solvents that can be used include for example alcohols, such as methanol, ethanol, propanol, isopropanol and butanol, aromatic hydrocarbons, such as benzene and toluene, ethers, such as dimethyl ether, diethyl ether, 1,2-dimethoxyethane, and tetrahydrofuran. Aqueous solutions or aqueous-organic solutions are preferred. In an aqueous-organic solution, the organic solution or the sum of the organic solvent components can represent a proportion by volume from 1 to 80 vol. %, preferably from 10 to 60 vol. %, and in particular about 40 vol. %. The aqueous-organic solutions or organic-aqueous solutions can be, within the scope of the invention, homogeneous solutions, or two- or multiphase systems (for example oil-in-water, water-in-oil, water-in-oil-in-water emulsions). To permit easy contact between enzyme and polyacrylic acid ester, the solutions are preferably not gel-like. The solutions preferably have viscosities of less than 4000 mPa*s, in particular less than 2000 mPa*s, less than 1000 mPa*s, less than 500 mPa*s, less than 400 mPa*s, less than 200 mPa*s, less than 100 mPa*s, less than 50 mPa*s, less than 25 mPa*s, less than 10 mPa*s, less than 5 mPa*s or less than 2.5 mPa*s. The aqueous solution or the aqueous component of an aqueous-organic solution can be a buffer. The pH of the buffer is preferably adjusted to the pH at which the enzyme-catalyzed ester cleavage is to take place. If the method according to the invention is carried out in a bioreactor, in which microorganisms that produce at least one esterase, which cleaves the at least one polyacrylic acid ester, then the pH is preferably adjusted to a value suitable for the cultivation of the microorganism. A person skilled in the art is familiar with the determination of suitable pH values. Suitable buffers for use in the method according to the invention are also known by a person skilled in the art and comprise for example PBS, Tris-HCl buffer, triethanolamine hydrochloride/NaOH buffer, diethanolamine/HCl buffer, sodium borate/HCl buffer, glycine/NaOH buffer, sodium carbonate/sodium bicarbonate buffer, Na₂HPO₄/NaOH buffer, 2-(cyclohexylamino)ethanesulfonic acid/NaOH buffer and 3-(cyclohexylamino)-1-propanesulfonic acid/NaOH buffer. Other buffer systems are known by a person skilled in the art, and are described for example in Harris and Angal (Eds.), Protein purification methods—a practical approach, IRL Press at Oxford University Press, 1st edition (reprint) 1990.

The method according to the invention can be carried out at all temperatures at which the esterases used are active, for example at temperatures from 5° C. to 85° C., preferably from 10° C. to 50° C., especially preferably from 20° C. to 40° C. A person skilled in the art is familiar with the fact that enzymes have optimal temperatures with respect to their stability and/or their catalytic activity, which may possibly also vary depending on the solvent or solvent mixture used, and can determine the optimum temperature or the optimum temperature range for each esterase used. If the method according to the invention is carried out using microorganisms that produce the at least one esterase that is used for the hydrolytic cleavage of the polyacrylic acid ester, then the temperature requirements of the microorganisms can also be taken into account by a person skilled in the art when selecting the process temperature.

The polyacrylic acid esters prepared can be esterified completely (i.e. each acrylic acid group is esterified with an alcohol or alcohol derivative) or esterified partially (i.e. there are still free acrylic acid groups in the molecule of the polyacrylic acid ester). According to preferred embodiments the polyacrylic acid ester prepared or the polyacrylic acid esters prepared is/are esterified completely or substantially completely. Esterification is substantially complete when at least 75%, in particular at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% of the acrylic acid groups of the polyacrylic acid have been esterified. Accordingly, substantially completely esterified polyacrylic acid esters have for example degrees of esterification of 75% to 100%, 75% to 99%, 75% to 98%, 75% to 97%, 75% to 96%, 75% to 95%, 85% to 100%, 85% to 99%, 85% to 98%, 85% to 97%, 85% to 96%, 85% to 95%, 90% to 100%, 90% to 99%, 90% to 98%, 90% to 97%, 90% to 96%, 90% to 95%, 95% to 100%, 95% to 99%, 95% to 98%, 95% to 97% or 95% to 96%.

The method according to the invention can take place in batch mode, or continuously. In batch mode, the at least one polyacrylic acid ester and the at least one esterase are prepared, incubation is carried out and at a chosen point of time the reaction mixture is discharged from the reaction vessel and optionally sent for further processing (for example isolation of the reaction product or recovery of the at least one esterase). Discharge can take place after completion of ester cleavage (i.e. after establishment of an equilibrium between polyacrylic acid ester on the one hand and polyacrylic acid or partially esterified polyacrylic acid on the other hand) or after incomplete ester cleavage. The suitable point of time for discharge of the respective batch can be determined by a person skilled in the art by various methods, for example by prior sampling and analysis, or by continuous monitoring of the course of reaction on the basis of suitable parameters, for example the pH or the viscosity of the solution, which vary as ester cleavage progresses. The batch can optionally also be discharged at the end of a predetermined reaction time. In batch mode, after initial provision of the at least one polyacrylic acid ester and the at least one esterase, before final discharge of the reaction mixture, a single or multiple further addition of polyacrylic acid ester and/or esterase can take place independently of one another. In continuous mode, after the initial provision of the at least one polyacrylic acid ester and the at least one esterase, at specified points of time a portion of the reaction mixture is discharged and the reaction mixture remaining in the reaction vessel is supplemented by adding polyacrylic acid ester and/or esterase. The time points can be periodical or can be selected depending on measurements of the course of reaction. Continuous addition of the at least one polyacrylic acid ester and/or of the at least one esterase is also possible. Independently of this, continuous discharge of the reaction mixture is also possible. A person skilled in the art knows how to optimize the individual process variables (e.g. amount and point of time of addition or discharge), in order to obtain the desired reaction product. Continuous operation can take place for different lengths of time, for example for hours, days, weeks, months or years, and can be interrupted or halted, for example for cleaning, inspection or maintenance.

If isolation of the modified polymer obtained as a result of ester cleavage is envisaged, this can take place by the methods usually employed in this field, for example by chromatographic methods, dialysis, chemical precipitation, solvent extraction or evaporation of the solvent contained in the reaction mixture. If the at least one esterase is to be reused, it can be separated by the methods usually employed in this field, preferably before isolation of the modified polymer takes place by methods that may possibly damage the enzyme. The esterase can be separated for example by affinity purification by means of esterase-binding molecules (for example antibodies), dialysis or precipitation (for example with ammonium sulfate). According to further embodiments the at least one esterase is present in immobilized form. Various methods of immobilization are known by a person skilled in the art, and are described for example in S. Fukui, A. Tanaka, “Enzymes”, in: Ullmann's Encyclopedia of Industrial Chemistry, 5th edition, Wiley-VCH, New York, Berlin, 1985; J. E. Prenosil, O. M. Kut, I. J. Dunn, E. Heinzle, “Immobilized Biocatalysts”, in: Ullmann's Encyclopedia of Industrial Chemistry, 6th edition, VCH, New York, Berlin, 2003, p. 503-554; J. F. Kennedy, J. M. S. Cabral, in: H. J. Rehm, G. Reed (Eds.), Biotechnology: A comprehensive treatise in 8 volumes; Vol. 7a, p. 349-404; VCH, Weinheim, 1987. A noncovalent binding of the enzyme can for example be achieved by labeling the enzyme with biotin and immobilization on a support provided with avidin or streptavidin, labeling of the enzyme by incorporating histidine tags in its amino acid sequence and immobilization on a support provided with nickel chelate, immobilization of the enzyme by antibodies directed against the enzyme (the binding epitopes preferably being selected so that the binding between antibody and binding epitope does not, or does not substantially, impair access of substrate molecules to the active site), production of fusion proteins from the enzyme and a foreign protein and immobilization of the protein by antibodies directed against the foreign protein, or by adsorptive adhesion on microspheres (beads) or on carrier materials. As a result of immobilization, the esterase molecules remain stationary in the reaction vessel (for example on the walls of the reaction vessel or on surfaces present in the reaction vessel) and during discharge of the reaction mixture, only the polyacrylic acid esters and/or the polymers modified by ester cleavage are discharged. Alternatively, in the case of adhesion on microspheres, the esterase molecules can be freely floating in the reaction solution and can interact with the polyacrylic acid ester molecules, but are prevented by various means (for example filters or the use of fluidized-bed reactors) from leaving the reaction vessel together with the polyacrylic acid ester molecules and/or the polyacrylic acid molecules. Discharge of the microspheres together with the polyacrylic acid ester molecules and/or the polyacrylic acid molecules and subsequent separation, for example by centrifugation or filtration, is also possible.

The method according to the invention can be carried out until partial or complete hydrolytic cleavage of the ester groups contained in the polyacrylic acid ester has occurred, and in the case of complete hydrolysis, polyacrylic acid would be obtained. Discharge after partial hydrolysis is preferred. In this case the initially supplied polyacrylic acid esters still contain ester groups, which endowed the polymers modified in the course of the reaction with certain properties. The modified polymer can then be used for further purposes, for example as starting substances for further chemical modifications.

2. Enzymes

In the method according to the invention it is possible to use esterases in general, and in particular enzymes that act on ester bonds, of EC class 3.1 according to the classification of the “Nomenclature Committee of the International Union of Biochemistry and Molecular Biology”. The classification of the EC classes is given in “Enzyme Nomenclature”, published in 1992 by Academic Press for the International Union of Biochemistry and Molecular Biology” under ISBN 0-12-227164-5, with subsequent supplements, or online on the Internet at http://www.chem.qmul.ac.uk/iupac/jcbn/index.html#6. Preferred embodiments are carboxylic acid ester hydrolases (E.C. 3.1.1), in particular carboxyl esterases (E.C. 3.1.1.1), triacylglycerol lipases (E.C. 3.1.1.3) and cutinases (E.C. 3.1.1.74).

For the methods according to the invention, it is also possible to use “functional mutants” (also called “functional esterase mutants”, “esterase mutants” or “mutants”) of the concretely disclosed esterases, with the functional mutants, optionally after isolation from a microorganism producing these, themselves being an object of the invention. Within the scope of the present invention, functional mutants are polypeptides that differ from the concretely disclosed esterases, e.g. those that are less than 100% identical to the esterases according to SEQ ID NO:1 to SEQ ID NO:38 (for Example 40% to less than 100%, 50% to less than 100%, 60% to less than 100%, 75% to less than 100%, 85% to less than 100%, 90% to less than 100%, 95% to less than 100% or 99% to less than 100%), but which still possess the desired enzyme activity. The desired enzyme activity can for example be detected by cleavage of polyacrylic acid esters, for example polyacrylic acid methyl esters or polyacrylic acid butyl esters. The desired enzyme activity is regarded as present if the functional mutant has at least 10% of the cleavage activity of the esterase (which can be determined for example as conversion of the substrate in unit time), taken as reference, in particular at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or 100% of said cleavage activity. The desired enzyme activity is of course in particular also present if the functional mutant has a higher cleavage activity than the esterase taken as reference, for example up to 105%, 110%, 120%, 150%, 200% or more than 200% of the cleavage activity of the esterase in question. Furthermore, it is also present if the functional mutant is able to cleave a new substrate, i.e. a polyacrylic acid ester that is not, or under comparable reaction conditions (for example temperature, pH, solvent or solvent composition, salt concentration, substrate concentration, enzyme concentration) is not, cleaved by the esterase taken as reference.

“Functional mutants” means, according to the invention, in particular altered proteins, which in at least one of the sequence positions of the aforementioned concrete sequences, have a different amino acid than that concretely stated, but nevertheless possess the desired enzyme activity. “Functional mutants” therefore comprise the altered proteins obtainable by one or more, e.g. 1-50, 1-40, 1-30, or 1-20, i.e. for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 amino acid additions, substitutions, deletions and/or inversions, and the stated changes can occur in any sequence position, provided they lead to a functional mutant with the profile of properties according to the invention. Functional mutants are in particular also present when the pattern of reactivity between mutant and unaltered polypeptide coincides qualitatively, i.e. for example the enzymatic parameters (for example substrate affinity, turnover number) are identical, but quantitatively are present to different degrees. Examples of suitable substitutions of amino acid residues are as follows:

Original residue Examples of substitution Ala Val, Gly, Ser Arg Lys Asn Gln; His Asp Glu Cys Ser Gln Asn Glu Asp Gly Pro His Asn; Gln Ile Leu; Val Leu Ile; Val Lys Arg; Gln; Glu Met Leu; Ile Phe Met; Leu; Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp; Phe Val Ile; Leu

“Functional mutants” in the above sense are also precursors of the esterases described and functional derivatives and salts of the esterases. The term “salts” means salts of carboxyl groups as well as salts of acid addition of amino groups of the protein molecules according to the invention. Salts of carboxyl groups can be prepared in a manner known per se and comprise inorganic salts, for example sodium, calcium, ammonium, iron and zinc salts, and salts with organic bases, for example amines, such as triethanolamine, arginine, lysine, piperidine and the like. Salts of acid addition, for example salts with mineral acids, such as hydrochloric acid or sulfuric acid and salts with organic acids, such as acetic acid and oxalic acid, are also covered by the invention. “Functional derivatives” of esterases described in the invention or functional esterase mutants according to the invention can also be prepared on functional amino acid sides groups or at their N- or C-terminal ends by known techniques. Derivatives of this kind comprise for example aliphatic esters of carboxylic acid groups, amides of carboxylic acid groups, obtainable by reaction with ammonia or with a primary or secondary amine; N-acyl derivatives of free amino groups, prepared by reaction with acyl groups; or O-acyl derivatives of free hydroxyl groups, prepared by reaction with acyl groups.

“Functional mutants” naturally also comprise esterases that are accessible from other organisms, and naturally occurring variants. For example regions of homologous sequence regions can be found by sequence comparisons and, on the basis of the concrete guidelines of the invention, functional mutants can be determined. Examples of organisms are Burkholderia (for example B. gladioli, B. mallei, B. pseudomallei, B. thailandensis, B. cenocepacia, B. aurantiaca, B. vietnamensis, B. dolosa, B. multivorans, B. ambifaria), Stigmatella (for example S. aurantiaca), Streptomyces (for example S. ambofaciens, S. coelicolor), Saccharopolyspora (for example S. erythraea), Mycobacterium (for example M. smegmatis, M. bovis, M. tuberculosis, M. leprae).

“Functional mutants” are moreover fusion proteins, which have one of the aforementioned polypeptide sequences of esterases or functional mutants derived therefrom and at least one further, functionally different therefrom, heterologous sequence in functional N- or C-terminal linkage (i.e. without mutual, substantial functional impairment of the fusion protein portions). Nonlimiting examples of heterologous sequences of this kind are e.g. enzymes, protein A and immunoglobulins, it being possible for protein A and immunoglobulin fusions to be used for example for noncovalent immobilization of the functional mutants on supports (for example microspheres).

Furthermore, methods of production of functional mutants are known by a person skilled in the art. Methods for modifying genes and therefore for modifying the proteins encoded by these have long been familiar to a person skilled in the art, for example site-directed mutagenesis, in which there is targeted exchange of individual or several nucleotides of a gene (Trower M K (ed.) 1996; In vitro mutagenesis protocols. Humana Press, New Jersey), saturation mutagenesis, in which a codon for any desired amino acid can be exchanged or added at any point of a gene (Kegler-Ebo D M, Docktor C M, DiMaio D (1994) Nucleic Acids Res 22:1593; Barettino D, Feigenbutz M, Valcárel R, Stunnenberg H G (1994) Nucleic Acids Res 22:541; Barik S (1995) Mol Biotechnol 3:1), error-prone polymerase chain reaction (error-prone PCR), in which nucleotide sequences are mutated by defectively operating DNA polymerases (Eckert K A, Kunkel T A (1990) Nucleic Acids Res 18:3739); passaging of genes in mutator strains, in which there is an increased mutation rate of nucleotide sequences, for example owing to defective DNA repair mechanisms (Greener A, Callahan M, Jerpseth B (1996) An efficient random mutagenesis technique using an E. coli mutator strain. In: Trower M K (ed.) In vitro mutagenesis protocols. Humana Press, New Jersey), or DNA shuffling, in which a pool of closely related genes is formed and digested and the fragments are used as template for a polymerase chain reaction, in which by repeated strand separation and bringing together again, full-length mosaic genes are finally produced (Stemmer W P C (1994) Nature 370:389; Stemmer W P C (1994) Proc Natl Acad Sci USA 91:10747). Depending on the technology used, a person skilled in the art can insert completely random or also more targeted mutations into genes or also noncoding nucleic acid regions (which for example are important for the regulation of expression) and then set up gene banks. The methods of molecular biology required for this are known by a person skilled in the art and for example are described in Sambrook and Russell, Molecular Cloning. 3rd edition, Cold Spring Harbor Laboratory Press 2001.

Using so-called directed evolution (described inter alia in Reetz M T and Jaeger K-E (1999), Topics Curr Chem 200:31; Zhao H, Moore J C, Volkov A A, Arnold F H (1999), Methods for optimizing industrial enzymes by directed evolution, in: Demain A L, Davies J E (Eds.) Manual of industrial microbiology and biotechnology. American Society for Microbiology), a person skilled in the art can also produce functional mutants in a targeted manner and on a large scale. In this, in a first step, gene banks of the respective proteins are first produced, for example employing the methods mentioned above. The gene banks are expressed in a suitable manner, for example by bacteria or by phage display systems. Moreover, methods are known by a person skilled in the art for controlling, by the choice of suitable expression vectors, the localization of the protein in the host, for example as intracellular proteins in the cytoplasm, as membrane protein by adding-on a membrane anchor, or as extracellular protein by adding-on a signal peptide with recognition site for a signal peptidase. Then in a second step, clones that express proteins with a desired property are selected or screened. During selection, only the clones that express proteins with desired properties survive, as these provide the host organisms with a survival advantage (for example enzymes that enable certain substrates to be utilized, or growth at certain temperatures). During screening, all clones survive, so that suitable assays are used for determining which one of the clones expresses a protein with the desired property. A person skilled in the art knows how assays can be suitably set up for the particular purpose. For example, when searching for proteins with specified binding properties, it is possible to screen for host organisms that express the proteins in question on their surface and adhere to a substrate coated with the binding partner (in contrast to host organisms that do not express functional proteins); when searching for functional mutants with catalytic properties, host organisms can for example be cultivated in microtiter plates with substrate-containing medium or on substrate-containing agar plates and the presence of functional mutants (optionally after lysis of the host organisms, to permit contact with the medium) can be indicated for example by color reactions after reaction of the substrate. In this connection it is possible to use automated systems (e.g. pipeting robots for microtiter plates, screening robots, image recognition systems for identifying colonies on agar plates), to make high-throughput screening possible. The relevant genes of host organisms that express functional mutants with properties that largely correspond to the desired properties are submitted to another round of mutation. The steps of mutation and of selection or screening can, on the other hand, be repeated iteratively until the functional mutants that are present have the desired properties to a sufficient degree.

Using an iterative procedure it is possible to conduct targeted screening for proteins with desired properties, although the insertion of many mutations into a protein sequence is more likely to lead to the loss of a function than to the acquisition or improvement of a desired function. Within the scope of the iterative procedure, we start from a reference protein, for example a wild-type protein, and prepare, on the basis of its nucleotide sequence, a gene library with mutations. For this, the mutation rate is selected at the nucleotide level so that following expression of the mutated nucleic acids, only a relatively small number of amino acids in the translated peptides or proteins have been mutated, for example 1 to 3 amino acids. The mutated peptides or proteins obtained are screened for representatives with desired properties (for example a higher catalytic activity for one or more substrates, an expanded or altered substrate spectrum, improved stability at increased or altered temperatures or pH values or in certain solvents). On the basis of the sequences of peptides or proteins found with the desired properties (which possibly are only slight), a second gene library is constructed, in which once again a relatively small rate of mutations is introduced, and the proteins translated from it are again screened for the desired property. This cycle of constructing a mutated gene library and screening of the peptides or proteins expressed from it for desired properties can be repeated as often as required. On the one hand, because of the low mutation rate used per cycle, it is avoided that practically all proteins have a loss of function because of too many mutations in their amino acid sequence, and on the other hand, through iterative repetition of mutation and selection, favorable mutations are accumulated and so finally there is a good prospect of success in preparing proteins that have the desired, greatly improved properties. Furthermore, through sequence analysis of mutants with improved properties, a person skilled in the art obtains sequence information that indicates to him which sequence positions or sequence regions of a peptide or protein are important for a desired property. Based on this information, he can intentionally put mutations at these sites or in these regions and accordingly obtain even more targeted mutants with desired properties. Examples in the literature for the production of proteins with desired properties, from which the relevant methods of production of mutations can also be seen, are described in Zhao and Arnold, Protein Engineering 12:47-53 (1999) or May et al., Nature Biotechnology 18:317-320 (2000).

Other “functional mutants” included according to the invention are homologs of the concretely disclosed esterases. These possess at least 40% or at least 50%, or at least 60%, e.g. at least 75% or in particular at least 85%, e.g. 90%, 95% or 99%, homology to one of the concretely disclosed sequences, e.g. calculated according to the algorithm of Pearson and Lipman, Proc. Natl. Acad, Sci. (USA) 85(8), 1988, 2444-2448. A percentage homology of a homologous polypeptide according to the invention means in particular the percentage identity of the amino acid residues relative to the total length of one of the amino acid sequences concretely described herein.

A “derived” amino acid sequence means according to the invention, if no other information is given, a sequence that has identity with the starting sequence of at least 80% or at least 90%, in particular about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99%. For example, the invention relates to the amino acid sequences derived from all amino acid sequences disclosed here.

“Identity” or “homology” between two sequences means identity of the amino acid residues over the whole sequence length in each case, e.g. the identity that is calculated by comparison using the Vector NTI Suite 7.1 Software from the company Informax (USA) using the clustal method (Higgins D G, Sharp P M. Fast and sensitive multiple sequence alignments on a microcomputer. Comput Appl. Biosci. 1989 April; 5(2): 151-1) on setting the following parameters:

Multiple Alignment Parameters:

Gap opening penalty 10 Gap extension penalty 10 Gap separation penalty range  8 Gap separation penalty off % identity for alignment delay 40 Residue specific gaps off Hydrophilic residue gap off Transition weighing  0

Pairwise Alignment Parameters:

FAST algorithm on K-tuplesize 1 Gap penalty 3 Window size 5 Number of best diagonals 5

These values can be varied further if necessary by a person skilled in the art in relation to the concrete sequences to be compared.

In the case of a possible protein glycosylation, the functional mutants according to the invention comprise proteins of the type designated above in deglycosylated or glycosylated form and modified forms obtainable by altering the glycosylation pattern.

Homologs of the esterases described or of their functional mutants according to the invention can be identified by screening combinatorial banks of mutants, e.g. shortened mutants. For example, a bank of peptide variants can be produced by combinatorial mutagenesis at the nucleic acid level, e.g. by enzymatic ligation of a mixture of synthetic oligonucleotides. There are many methods that can be used for the production of banks of potential homologs from a degenerated oligonucleotide sequence. The chemical synthesis of a degenerated gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic gene can then be ligated into a suitable expression vector. The use of a degenerated set of genes makes it possible to provide all sequences in one mixture, which encode the desired set of potential protein sequences. Methods of synthesis of degenerated oligonucleotides are known by a person skilled in the art (e.g. Narang, S. A. (1983) Tetrahedron 39:3; Itakura et al. (1984) Annu. Rev. Biochem. 3:323; Itakura et al. (1984) Science 198:1056; Ike et al. (1983) Nucleic Acids Res. 11:477).

Within the scope of the research forming the basis of the present invention, the inventors found, surprisingly, that ester bonds of polyacrylic acid esters, i.e. polymer substrates, can be cleaved by esterases. Esterases from various organisms can be used, and the following may be mentioned as nonlimiting examples: Burkholderia (for example B. gladioli, B. mallei, B. pseudomallei, B. thailandensis, B. cenocepacia, B. aurantiaca, B. vietnamensis, B. dolosa, B. multivorans, B. ambifaria), Stigmatella (for example S. aurantiaca), Streptomyces (for example S. ambofaciens, S. coelicolor), Saccharopolyspora (for example S. erythraea), Mycobacterium (for example M. smegmatis, M. bovis, M. tuberculosis, M. leprae).

Esterases that are preferred for carrying out the method according to the invention are enzymes that act on ester bonds in EC class 3.1, in particular carboxylic acid ester hydrolases (EC 3.1.1). Carboxyl esterases, triacylglycerol lipases and cutinases are especially preferred. Esterases of family VIII (in particular esterase B from Burkholderia gladioli according to SEQ ID NO:1 and functional mutants thereof) and type C esterases (in particular esterase C from Burkholderia gladioli according to SEQ ID NO:2 and functional mutants thereof) represent further special embodiments. Other, nonlimiting examples of usable esterases are the sequences according to SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, on the basis of which functional mutants can in their turn be produced or derived.

Within the scope of the present invention, furthermore, functional mutants of known esterases were therefore produced, which can also be used in the method according to the invention and furthermore—optionally after isolation from a microorganism producing the functional mutants—are themselves also covered by the invention.

These functional mutants relate in particular to esterases with an altered amino acid sequence relative to the known wild type, with a new esterase being provided by the altered sequence, with which optionally the access of polymer substrates to the catalytically active site is made possible or is facilitated, and/or the stability of the esterase is increased, for example the stability at certain pH values or in various solvents or solvent mixtures are covered by the invention, therefore among other things functional mutants of esterases, in which structural elements are altered or removed, which prevent or impede the access of substrates to the active site, for example loops. Suitable regions for loop shortening in the case of an esterase according to SEQ ID NO:1 (EstB from B. gladioli) are for example the regions Glu246 to Arg 258 and Gly312 to 323. In this case loop shortenings can be carried out by removing one or more amino acids, and in the case of removal of several amino acids, once again one or more amino acids with adjacent or nonadjacent location in SEQ ID NO:1 can be removed. The invention relates furthermore to functional mutants of esterases, in which the access to the catalytically active site (also called active center), which can for example be of tunnel, funnel, furrow or crevice shape, was made more accessible for molecules from the surroundings of the esterase. This can take place for example by removing amino acids with large side chains, which are a constituent of the access to the catalytically active site, or replacing them with amino acids with smaller side chains (for example alanine with glycine, valine with alanine or glycine, leucine with valine, etc.). As a result the spatial access of partial regions of polyacrylic acid esters, which are macromolecules with large space filling, to the catalytic center is made possible or facilitated. Regarding the charging of polyacrylic acid esters, which can have a negative charge because there are still free carboxyl groups, this can moreover take place by exchange of acidic amino acids in the access region of the active site for neutral or basic amino acids. With regard to polyacrylic acid esters, which for example because of alcohol constituents of the ester substituted with basic groups can rather have a positive charge, the access to the catalytically active site can correspondingly be made possible or facilitated by exchange of basic amino acids in the access region of the catalytically active site for less basic, optionally neutral or acidic amino acids. For example, suitable amino acids, exchange of which for amino acids with smaller side chains should improve the access to the active site, are Tyr181, Trp348 and Trp149 in the case of SEQ ID NO:1. For SEQ ID NO:2, for example Leu163, Val213 and Pro168 are possibilities for this, and especially in the case of Pro168, exchange for Ala or Gly can also increase the flexibility of the associated loops, so that a larger substrate can be allowed. The invention further relates to functional mutants of esterases with increased stability, for example increased pH, temperature or solvent stability. This increased stability can for example be achieved by amino acid exchanges, with which intramolecular interactions within a protein molecule become possible for the first time or are intensified, by which there is better fixation of unstable loops of the protein molecule, or individual protein domains acquire better cohesion.

Accordingly, special embodiments of the present invention are functional mutants of EstB according to SEQ ID NO:1, in which loops positioned above the catalytically active site were removed or shortened by more or less complete deletion of the loop-forming amino acids. FIG. 1 shows a molecular model of EstB according to SEQ ID NO:1, in which two loops were identified, which lie between the catalytically active site and the external medium of the EstB.

Further special embodiments of the present invention are accordingly functional mutants of EstC according to SEQ ID NO:2. Within the scope of the present invention, a structural model of EstC was used, on the basis of which functional mutants were produced. In this connection, the inventors identified protein regions that line the access to the catalytically active site. Next, by site-directed mutagenesis, individual or several amino acids of SEQ ID NO:2 were intentionally altered, in order to widen the access and provide better access for large, polymeric substrates. Phe138 (i.e. the phenylalanine on amino acid position 138) was identified as an amino acid lining the access to the active site (FIG. 2). It can be seen from FIG. 2 that Phe138 is positioned with its side chain between the amino acids Ser112, Asp242 and His275 of the catalytically active site and the external medium of the protein. By replacing Phe138 with alanine (Phe138Ala), in view of the smaller side group of alanine, the access of bulky substrate molecules, for example polyacrylic acid esters, to the catalytically active site is facilitated (corresponding to mutation 1K22 in FIG. 5). The physicochemical properties of the protein surface at position 138 remain essentially the same, as a hydrophobic amino acid is replaced with another hydrophobic amino acid. According to the invention, Leu193 was identified as another amino acid hampering access to the catalytically active site (FIG. 4), and in one embodiment was replaced with alanine (corresponding to mutation 2K20 in FIG. 5). Another example that may be mentioned is Thr188, which is located at the margin of the access to the catalytically active site and can still influence the access of substrate molecules to a certain extent (FIG. 4). According to one embodiment, Thr188 is replaced with serine, for example in the triple mutation Phe138Ala, Leu193Ala, Thr188Ser (FIG. 4). The invention covers any combinations of these or of the mutations shown in FIG. 5. A person skilled in the art is able, using the procedure described here, to determine suitable positions for amino acid exchange also in the case of proteins homologous to EstC. For example, using the “Tripos” software from Sybly (St. Louis, Mo., USA) he is able to superimpose the structure of EstC disclosed here and an esterase with similar 3D structure and then determine suitable positions, so that the present invention is not limited to the proteins and mutations concretely disclosed here.

3. Nucleic Acids

The invention further relates to the coding nucleic acid sequences for the functional esterase mutants described above, such as in particular according to SEQ ID NO:54 to SEQ ID NO:57.

All nucleic acid sequences according to the invention (single-stranded and double-stranded DNA and RNA sequences, e.g. cDNA and mRNA) can be produced in a manner known per se by chemical synthesis from the nucleotide building blocks, for example by fragment condensation of individual overlapping, complementary nucleic acid building blocks of the double helix. The chemical synthesis of oligonucleotides can take place for example, in a known way, by the phosphoroamidite method (Voet, Voet, 2nd edition, Wiley Press New York, pages 896-897). The adding-on of synthetic oligonucleotides and filling of gaps using the Klenow fragment of DNA polymerase and ligation reactions and general cloning methods are described in Sambrook et al. (1989), Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory Press.

A “derived” nucleic acid sequence means according to the invention, unless stated otherwise, a sequence that has identity with the starting sequence of at least 80% or at least 90%, in particular about 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% and 99%. The invention relates for example to all nucleic acid sequences derived from the nucleic acid sequences disclosed here.

“Identity” between two nucleic acids means identity of the nucleotides in each case over the full length of the nucleic acid, in particular the identity that is determined by comparison using the Vector NTI Suite 7.1 Software from the company Informax (USA) using the clustal method (see above).

The invention also relates to nucleic acid sequences coding for one of the above esterases and functional mutants thereof, which are accessible e.g. using artificial nucleotide analogs.

The invention relates both to isolated nucleic acid molecules, which code for esterases according to the invention or enzymatically active segments thereof, and nucleic acid fragments that can be used e.g. as hybridization probes or primers for identification or amplification of coding nucleic acids according to the invention.

The nucleic acid molecules according to the invention can moreover contain untranslated sequences from the 3′- and/or 5′-end of the coding gene region.

An “isolated” nucleic acid molecule is separated from other nucleic acid molecules that are present in the natural source of the nucleic acid and can moreover be substantially free of other cellular material or culture medium, if it is produced by recombinant techniques, or free from chemical precursors or other chemicals, if it is synthesized chemically.

A nucleic acid molecule according to the invention can be isolated by means of standard techniques of molecular biology and the sequence information provided according to the invention. For example, cDNA can be isolated from a suitable cDNA bank, using one of the complete sequences concretely disclosed or a segment thereof as hybridization probe and standard hybridization techniques (as described for example in Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A laboratory manual. 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989). Moreover, a nucleic acid molecule, comprising one of the sequences according to the invention or a segment thereof, can be isolated by polymerase chain reaction, using the oligonucleotide primers that were prepared on the basis of this sequence. The nucleic acid thus amplified can be cloned into a suitable vector and can be characterized by DNA sequence analysis. The oligonucleotides according to the invention can moreover be produced by standard methods of synthesis, e.g. with an automatic DNA synthesizer.

The invention further comprises the nucleic acid molecules that are complementary to the concretely described nucleotide sequences, or a segment thereof.

The nucleotide sequences according to the invention make possible the production of probes and primers, which can be used for the identification and/or cloning of homologous sequences in other cell types and organisms. Such probes or primers usually comprise a nucleotide sequence region, which hybridizes under stringent conditions to at least about 12, preferably at least about 25, e.g. about 40, 50 or 75 successive nucleotides of a sense strand of a nucleic acid sequence according to the invention or a corresponding antisense strand.

Further nucleic acid sequences according to the invention are derived from coding sequences of the esterases according to the invention and differ from them by one or more, e.g. 1-50, 1-40, 1-30, or 1-20, i.e. for example 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 additions, substitutions, insertions or deletions of individual or several nucleotides, but furthermore code for esterases with the desired enzyme activity.

The invention also relates to nucleic acid sequences that comprise so-called silent mutations or have been altered according to the codon usage of a special original or host organism, in comparison with a concretely stated sequence, as well as naturally occurring variants, e.g. splice variants or allele variants, thereof. It also relates to sequences obtainable by conservative nucleotide substitutions (i.e. the amino acid in question is replaced with an amino acid of the same charge, size, polarity and/or solubility).

The invention also relates to molecules derived by sequence polymorphisms from the concretely disclosed nucleic acids.

These genetic polymorphisms can exist between individuals within a population due to natural variation. These natural variations usually bring about a variance of 1 to 5% in the nucleotide sequence of a gene.

Furthermore, the invention also comprises nucleic acid sequences that hybridize to the aforementioned coding sequences or are complementary to them. These polynucleotides can be found by inspecting genome or cDNA libraries and can optionally be amplified from them with suitable primers by means of PCR and then isolated for example with suitable probes. Another possibility is the transformation of suitable microorganisms with polynucleotides or vectors according to the invention, multiplication of the microorganisms and therefore of the polynucleotides and subsequent isolation thereof. Furthermore, polynucleotides according to the invention can also be synthesized chemically.

The property of being able to “hybridize” to polynucleotides means the capacity of a polynucleotide or oligonucleotide to bind under stringent conditions to an almost complementary sequence, whereas under these conditions nonspecific bindings between noncomplementary partners do not occur. For this the sequences should be complementary to 70-100%, in particular to 90-100%, e.g. 95%, 96%, 97%, 98% or 99%. The property of complementary sequences of being able to bind specifically to one another is utilized for example in Northern or Southern blotting or in primer binding in PCR or RT-PCR. Usually oligonucleotides starting from a length of 30 base pairs are used for this. “Under stringent conditions” means, for example in Northern blotting, the use of a washing solution at a temperature of 50-70° C., preferably 60-65° C., for example 0.1×SSC buffer with 0.1% SDS (20×SSC: 3M NaCl, 0.3M Na-citrate, pH 7.0), for elution of nonspecifically hybridized cDNA probes or oligonucleotides. As mentioned above, only highly complementary nucleic acids remain bound to one another. The establishment of stringent conditions is known by a person skilled in the art and is described e.g. in Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6.

4. Expression Constructs and Vectors

The invention further relates to expression constructs, containing, under the genetic control of regulatory nucleic acid sequences, a nucleic acid sequence coding for an esterase according to the invention or a functional mutant; and vectors, comprising at least one of these expression constructs.

Preferably said constructs according to the invention comprise, 5′-upstream of the respective coding sequence, a promoter and, 3′-downstream, a terminator sequence and optionally other usual regulatory elements, in each case operatively linked to the coding sequence. “Operative linkage” means the sequential arrangement of promoter, coding sequence, terminator and optionally other regulatory elements in such a way that each of the regulatory elements can fulfill its function in expression of the coding sequence as defined. Examples of operatively linkable sequences are targeting sequences and enhancers, polyadenylation signals and the like. Other regulatory elements comprise selectable markers, amplification signals, replication origins and the like. Suitable regulatory sequences are described e.g. in Goeddel, Gene Expression Technology Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990).

In addition to the artificial regulatory sequences, the natural regulatory sequence can still be present in front of the actual structural gene. Through genetic variation, this natural regulation may possibly be switched off and the expression of the genes can be increased or reduced. The gene construct can, however, also be of simpler construction, i.e. no additional regulatory signals are inserted before the structural gene and the natural promoter with its regulation is not removed. Instead the natural regulatory sequence is mutated so that there is no longer any regulation and gene expression is increased or decreased. The nucleic acid sequences can be contained in the gene construct in one or more copies.

Examples of usable promoters are: cos-, tac-, trp-, tet-, trp-tet-, lpp-, lac-, lpp-lac-, laclq-, T7-, T5-, T3-, gal-, trc-, ara-, SP6-, lambda-PR- or lambda-PL promoters, which advantageously find application in Gram-negative bacteria; and the Gram-positive promoters amy and SPO2, the yeast promoters ADC1, MFalpha, AC, P-60, CYC1, GAPDH or the plant promoters CaMV/35S, SSU, OCS, lib4, usp, STLS1, B33, not or the ubiquitin or phaseolin promoter. The use of inducible promoters, e.g. light- and in particular temperature-inducible promoters, such as the P_(r)P_(l)-promoter, is especially preferred. In principle all natural promoters can be used with their regulatory sequences. Furthermore, synthetic promoters can also be used advantageously.

The aforementioned regulatory sequences should permit targeted expression of the nucleic acid sequences and of protein expression. This can mean for example, depending on the host organism, that the gene is only expressed or overexpressed after induction, or that it is expressed and/or overexpressed immediately.

The regulatory sequences or factors can preferably have a positive influence on expression and thus cause it to increase or decrease. Thus, a strengthening of the regulatory elements can advantageously take place at the transcription level, by using strong transcription signals such as promoters and/or “enhancers”. In addition, however, an intensification of translation is also possible, for example with improvement of the stability of mRNA.

An expression cassette is produced by fusion of a suitable promoter with a suitable coding nucleotide sequence and a terminator or polyadenylation signal. Common recombination and cloning techniques are used for this, as described for example in T. Maniatis, E. F. Fritsch and J. Sambrook, Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989) and in T. J. Silhavy, M. L. Berman and L. W. Enquist, Experiments with Gene Fusions, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1984) and in Ausubel, F. M. et al., Current Protocols in Molecular Biology, Greene Publishing Assoc. and Wiley Interscience (1987).

The recombinant nucleic acid construct or gene construct is inserted for expression in a suitable host organism, advantageously into a host-specific vector, which makes optimal expression of the genes in the host possible. Vectors are well known by a person skilled in the art and can be taken for example from “Cloning Vectors” (Pouwels P. H. et al., Eds., Elsevier, Amsterdam-New York-Oxford, 1985). Vectors are to be understood as, in addition to plasmids, also all other vectors known by a person skilled in the art, for example phages, viruses, such as SV40, CMV, baculovirus and adenovirus, transposons, IS elements, phasmids, cosmids, and linear or circular DNA. These vectors can be replicated autonomously in the host organism or can be replicated chromosomally.

As examples of suitable expression vectors we may mention:

Usual fusion expression vectors, such as pGEX (Pharmacia Biotech Inc; Smith, D. B. and Johnson, K. S. (1988) Gene 67:31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT 5 (Pharmacia, Piscataway, N.J.), in which glutathione-S-transferase (GST), maltose E-binding protein or protein A are fused onto the recombinant target protein.

Non-fusion protein expression vectors such as pTrc (Amann et al., (1988) Gene 69:301-315) and pET 11d (Studier et al. Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990) 60-89).

Yeast expression vector for expression in the yeast S. cerevisiae, such as pYepSec1 (Baldari et al., (1987) EMBO J. 6:229-234), pMFa (Kurjan and Herskowitz (1982) Cell 30:933-943), pJRY88 (Schultz et al. (1987) Gene 54:113-123) and pYES2 (Invitrogen Corporation, San Diego, Calif.). Vectors and methods of construction of vectors that are suitable for use in other fungi, such as filamentous fungi, include those that are described in detail in: van den Hondel, C. A. M. J. J. & Punt, P. J. (1991) “Gene transfer systems and vector development for filamentous fungi, in: Applied Molecular Genetics of Fungi, J. F. Peberdy et al., Eds., p. 1-28, Cambridge University Press: Cambridge.

Baculovirus vectors, which are available for expression of proteins in cultured insect cells (for example Sf9 cells), comprise the pAc series (Smith et al., (1983) Mol. Cell Biol., 3:2156-2165) and the pVL series (Lucklow and Summers (1989) Virology 170:31-39).

Plant expression vectors, such as those that are described in detail in: Becker, D., Kemper, E., Schell, J. and Masterson, R. (1992) “New plant binary vectors with selectable markers located proximal to the left border”, Plant Mol. Biol. 20:1195-1197; and Bevan, M. W. (1984) “Binary Agrobacterium vectors for plant transformation”, Nucl. Acids Res. 12:8711-8721.

Mammalian expression vectors, such as pCDM8 (Seed, B. (1987) Nature 329:840) and pMT2PC (Kaufman et al. (1987) EMBO J. 6:187-195).

Other suitable expression systems for prokaryotic and eukaryotic cells are described in chapters 16 and 17 of Sambrook, J., Fritsch, E. F. and Maniatis, T., Molecular Cloning: A laboratory manual, 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

5. Recombinant Host Organisms

By means of the vectors according to the invention, recombinant organisms can be produced, which have for example been transformed with at least one vector according to the invention and can be used for the production of the domains or polypeptides according to the invention. Advantageously the recombinant constructs according to the invention, described above, are inserted into a suitable host system and expressed. Preferably, common cloning and transfection methods known by a person skilled in the art, for example co-precipitation, protoplast fusion, electroporation, chemical transformation, retroviral transfection and the like, are used in order to bring about expression of the stated nucleic acids in the particular expression system. Suitable systems are described for example in Current Protocols in Molecular Biology, F. Ausubel et al., Eds., Wiley Interscience, New York 1997, or Sambrook et al. Molecular Cloning: A laboratory manual. 2nd edition, Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.

As host organisms, in principle all organisms are suitable that make possible expression of the nucleic acids according to the invention, their allele variants, their derivations, which code for functional mutants, or derivatives thereof. The host organisms are for example bacteria, fungi, yeasts, plant or animal cells. Preferred organisms are bacteria, such as those of the genera Escherichia, e.g. Escherichia coli, Streptomyces, Bacillus, Pseudomonas or Burkholderia, eukaryotic microorganisms, such as Saccharomyces cerevisiae, Aspergillus, higher eukaryotic cells from animals or plants, for example Sf9, CHO or HEK293 cells, and within the scope of the present invention, individual cells from higher eukaryotic life forms such as animals or plants or said cells that have aggregated or grown to form cell clusters, are also designated as microorganisms.

The selection of successfully transformed organisms can be effected by means of marker genes, which are also contained in the vector or in the expression cassette. Examples of said marker genes are genes for antibiotic resistance and for enzymes that catalyze a coloring reaction, which produces a staining or a fluorescence of the transformed cell. These can then be selected by automatic cell sorting. Microorganisms successfully transformed with a vector, which carry a corresponding antibiotic resistance gene (e.g. G418 or hygromycin), can be selected with media or culture nutrients containing the corresponding antibiotics. Marker proteins that are presented on the cell surface can be used for selection by means of affinity chromatography.

The invention further relates to methods for recombinant production of esterases according to the invention or functional, enzymatically active fragments thereof, by cultivating an esterase-producing recombinant host organism, optionally inducing expression of the esterase and isolating the latter from the culture. The esterase or the esterases can also be produced in this way on an industrial scale, if this is required.

The recombinant host can be cultivated and fermented by known methods. Bacteria can be grown for example in TB or LB medium and at a temperature from 20 to 40° C. and a pH from 6 to 9. Suitable culture conditions are described in detail for example in T. Maniatis, E. F. Fritsch and J. Sambrook, Molecular Cloning: A laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989).

Then, if the esterases are not secreted in the culture medium, the cells are lysed and the product is obtained from the lysate by known protein isolation techniques. The cells can optionally be disrupted by high-frequency ultrasound, by high pressure, e.g. in a French pressure cell (French press), by osmolysis, by the action of detergents, lytic enzymes or organic solvents, by means of homogenizers or by a combination of several of the methods listed.

The esterases can be purified with known chromatographic methods, such as molecular sieve chromatography (gel filtration), such as Q-sepharose chromatography, ion exchange chromatography and hydrophobic chromatography, and with other usual methods such as ultrafiltration, crystallization, salting-out, dialysis and native gel electrophoresis. Suitable methods are described for example in Cooper, F. G., Biochemical Procedures, Verlag Walter de Gruyter, Berlin, New York or in Scopes, R., Protein Purification, Springer Verlag, New York, Heidelberg, Berlin.

It is especially suitable to use vector systems or oligonucleotides for isolating the recombinant esterase; these lengthen the cDNA by defined nucleotide sequences and therefore code for altered polypeptides or fusion proteins, which serve e.g. for simpler purification. Suitable modifications of this kind are for example so-called “tags”, functioning as anchorages, e.g. the modification known as hexa-histidine-anchor or epitopes that can be recognized as antigens by antibodies (described for example in Harlow, E. and Lane, D., 1988, Antibodies: A Laboratory Manual. Cold Spring Harbor (N.Y.) Press). These anchors can serve for adhesion of the peptides to a solid support, e.g. a polymer matrix, which can for example be used as packing in a chromatography column, or can be used on a microtiter plate or some other support.

At the same time, these anchors can also be used for recognition of the esterases. For recognition of the esterases, it is also possible to employ usual markers, such as fluorescence dyes, enzyme markers, which after reaction with a substrate form a detectable reaction product, or radioactive markers, alone or in combination with the anchors for derivatization of the esterases.

6. Reactors

The method according to the invention can be carried out in reactors that are usual in this field, and at various scales, for example at the laboratory scale (a few milliliters to dozens of liters) or on an industrial scale (liters to several thousand cubic meters). If the esterase is used in the form of an isolated, more or less purified enzyme, a chemical reactor can be used. If, within the scope of the method according to the invention, the esterase used is produced by a microorganism and optionally is released in the reaction medium, so that ester cleavage can take place there, then a bioreactor (fermenter) is used, in which as well as suitable process conditions for ester cleavage, suitable living conditions must also be provided for the esterase-producing microorganisms (e.g. by providing a suitable nutrient medium and pH, a suitable temperature, supply of oxygen or other gases, antibiotics, etc.). A bioreactor is therefore suitable for the preparation of the esterases by a whole-cell system, in which living microorganisms (for example prokaryotic cells such as bacteria or archaebacteria, or eukaryotic cells such as yeasts, mammalian cells or insect cells) are cultivated. A person skilled in the art is familiar with the various aspects of the use of reactors, for example the upscaling of chemical or biotechnological processes from the laboratory scale to large-scale industrial production and the optimization of process variables and can optionally refer to relevant technical literature (for biotechnological processes for example Crueger and Crueger, Biotechnologie—Lehrbuch der angewandten Mikrobiologie [Biotechnology—textbook of applied microbiology], 2nd edition, R. Oldenbourg Verlag, Munich, Vienna, 1984).

7. Reaction Products

The present invention also relates to the reaction products obtained by the method according to the invention. The reaction products can be present together with the reaction mixture used in the method according to the invention, or can be purified partially or extensively. Suitable degrees of purification can be determined routinely by a person skilled in the art as required and according to the further use and comprise for example chemical purity or analytical purity. Suitable methods for purification are known by a person skilled in the art and comprise for example precipitation and chromatographic methods.

The reaction products obtained, which depending on the degree of the preceding ester cleavage comprise polyacrylic acids or partially esterified polyacrylic acid, can be used for example in paints and coatings, such as wall paints, coatings (e.g. for metal surfaces, in particular in the automobile industry) and paint and varnish. There are other applications in the paper industry (e.g. for influencing printability, appearance or gloss), in adhesives and sealants, in the textile industry (e.g. as binders for pigment coloring or printing processes) or in the leather industry (for example to make the surface of leather hydrophobic). Further uses include the production of textile and glass fibers, polish for floors, cars or shoes, additives for hydraulic cements, mortar or concrete. Polyacrylates are also used in plant protection and the spreading of fertilizers and as matrices for ion exchangers. Applications for polymethacrylates (i.e. poly(methylmethacrylates)) include in particular the so-called acrylic glasses as well as additives for the petroleum industry, thickeners for dispersions and in the cosmetics industry. Polymethacrylates are also used as prostheses in dentistry, as bone cement in surgery and as pharmaceutical excipients in controlled-release tablets.

With the method according to the invention it is in particular possible to prepare regiospecifically modified polymers. It was found, surprisingly, that by using enzymes that only cause hydrolytic cleavage of terminal ester groups of the polymer molecule, but not ester groups deeper within the polymer molecule, polymers selectively modified in this way can be produced relatively simply in comparison with chemical methods.

The invention will now be explained in more detail with reference to the following nonlimiting examples.

EXPERIMENTAL SECTION Example 1 Production of an EstC Gene Bank

A gene library was produced with mutated EstC from Burkholderia gladioli (SEQ ID NO:51), in order to obtain functional mutants of EstC. Mutations were introduced in EstC by random mutagenesis, using the plasmid pMSP1.17 in error-prone PCR as template according to the protocol and, using the GeneMorph® II random mutagenesis kit (Stratagene), sequence errors were introduced into the PCR-amplified EstC genes. Lit: Instruction Manual GeneMorph® II Random Mutagenesis Kit (Cat# 200550). Next, the PCR-amplified genes were purified with the Promega Wizard SV Gel and PCR Clean-Up System according to the protocol and were cut with the restriction enzymes NdeI and HindIII in buffer R from Fermentas. Independently of that, the plasmid pMS470A8 as vector-DNA (Balzer et al., Nucleic Acids Research, 1992, Vol. 20, No. 8, 1851-1858) was digested with the same restriction enzymes, and after thermal inactivation of the restriction enzymes (80° C., 20 min) was dephosphorylated with 1 μl Calf Intestine Alkaline Phosphatase (CIAP) from Fermentas for 1 hour at 37° C. The total DNA was applied on an agarose gel, the corresponding vector portion was cut out and was purified with the Wizard SV Gel and PCR Clean-Up System from Promega according to the protocol. Then the vector-DNA and the inserts produced were ligated with T4 DNA ligase from Fermentas for 1 hour at 20° C. The ligation product was then purified with the Wizard SV Gel and PCR Clean-Up System from Promega and desalinated and transformed into competent E. coli BL21 (DE3) cells with the Micropulser™ from BioRad by electroporation (2.5 kV) of each 2 μl of the plasmid DNA in 80 μl. Immediately after electroshock the cells were taken up in 1 ml of SOC medium and regenerated for 35 min at 37° C. and 550 rpm in an Eppendorf “Thermomixer comfort”. The competent cells were produced according to “Current Protocols in Molecular Biology” 1.8.4. Transformed clones were selected on LB-Amp plates (100 μg/ml), 10 transformants were streaked on the aforementioned selection plates and were used for plasmid preparation according to QIAprep® Spin Miniprep Kit from Qiagen. The plasmids isolated were digested with the aforementioned restriction enzymes and the presence of an insert of the correct size was confirmed by agarose gel electrophoresis. In addition the mutation rate was determined by sequencing.

Example 2 Production of Mutated EstC Variants by Site-Directed Mutagenesis

The “QuickChange Multi-Site-directed Kit” from Stratagene (Catalog No. #200514 and #100515) was used for the site-directed mutagenesis, offering a rapid and reliable method for the site-directed mutagenesis of a plasmid DNA at up to five sites simultaneously. The mutation of each individual site requires a single mutagenic oligonucleotide, using a double-stranded DNA template. The following mutagenic oligonucleotide primers, which were devised according to the recommendations in the protocol of the QuickChange Multi-Site-directed Kit and were synthesized by Invitrogen, were used, with the mutations produced shown in parentheses:

SEQ ID NO: 39: (Phe138Val) 5′-gctgctcttgtatatcttgctgcggtcatgcctgc-3′ SEQ ID NO: 40: (Phe138Ala) 5′-gctgctcttgtatatcttgctgcggccatgcctgc-3′ SEQ ID NO: 41: (Glu154Ala) 5′-gtaagagcaccagcaaaccatggcgaaatgctggc-3′ SEQ ID NO: 42: (Leu163Ala) 5′-ctggcctcggcgatctgcgccagccct-3′ SEQ ID NO: 43: (Leu189Ala) 5′-cggcctatctcgccacggcgaagca-3′ SEQ ID NO: 44: (Leu189AlaLeu193Ala) 5′-gccacggcgaagcaggcggcgttcgaggatgttga-3′ SEQ ID NO: 45: (Leu193Ala) 5′-gcaggcggcgttcgaggatgttgac-3′ SEQ ID NO: 46: (Val150Ala) 5′-gtacctggtcttgattacgcgagagctcct-3′ SEQ ID NO: 47: (Thr188Ser) 5′-gcctatctcgcctcgctgaagcagg-3′ SEQ ID NO: 48: (Leu160Ala) 5′-cgaaatggcggcctcgctgatctgc-3′ SEQ ID NO: 50: (Thr188AlaLeu189AlaLeu193Ala) 5′-tatctcgcctcggcgaagcaggcggcgttcgagga-3′

For the site-directed mutagenesis, a double-stranded DNA template was produced, employing a usual protocol for DNA minipreparations (QIAprep Spin Miniprep Kit from Qiagen). Then the reaction mixture for the synthesis of the mutated strand was prepared by PCR according to the following schedule, the individual constituents being put in the reaction vessel in the order shown in the schedule, and then mixed:

Experimental Reaction:

2.5 μl 10×QuikChange multi-reaction buffer 2.0 μl ds-DNA template: pMS470[EstC] (50 ng) 1.0 μl dNTP-mix 1.0 μl QuikChange multi-enzyme mixture × μl mutagenic primer (when using 1-3 primers approx. 100 ng of each primer was added, when using 4-5 primers approx. 50 ng of each primer was added) × μl doubly distilled H₂O for a final volume of 25 μl

Control Reaction:

2.5 μl 10×QuikChange multi-reaction buffer 18.5 μl doubly distilled H₂O 1.0 μl (50 ng/μl) QuikChange multi-control template 1.0 μl QuikChange multi-control primer mixture (100 ng/μl per primer) 1.0 μl dNTP-mix 1.0 μl QuikChange multi-enzyme mixture

The reactions were carried out using the parameters given in Table 1 below, using, for the control reaction, a time of 8 minutes for strand synthesis:

TABLE 1 Segment Cycles Temperature Duration 1 1 95° C.  1 minute 2 30 95° C.  1 minute 55° C.  1 minute 65° C. 10 minutes

Then 1 μl of the restriction enzyme DpnI was added to each reaction mixture of the respective amplification reactions. Each reaction mixture was mixed carefully and thoroughly by taking it up into a pipet and then discharging it several times. Next, the reaction mixtures were centrifuged in a microcentrifuge for 1 min and then immediately incubated for 1 h at 37° C., in order to digest the parent (unmutated) double-stranded DNA.

Next, the PCR fragments obtained were purified after purification with the Promega Wizard SV Gel and PCR Clean-Up System according to the protocol and were digested with the restriction enzymes NdeI and HindIII in buffer R (Fermentas) and, by the procedure described in Example 1, were ligated into vector pMS470Δ8, also cut with the restriction enzymes NdeI and HindIII.

Then transformation of XL10-Gold Ultra-competent cells was performed according to the manufacturer's instructions (Stratagene).

For each transformation reaction, a suitable volume was plated on LB_(amp) plates according to the information in Table 2. For control of mutagenesis, the cells were plated on LB_(amp) plates that had been prepared with 80 μg/ml X-gal and 20 mM IPTG.

TABLE 2 Type of reaction Volume on the plate Experimental mutagenesis 1 μl, 10 μl and 100 μl Mutagenesis control 10 μl

The transformation plates were then incubated overnight at 37° C.

The number of colonies to be expected from the mutagenesis control transformation is between 50 and 800 colonies. More than 50% of the colonies from the mutagenesis control transformation should have all three mutations and should appear as blue colonies on IPTG- and X-gal-containing agar plates. The number of colonies to be expected from the experimental mutagenesis transformation is between 10 and 1000 colonies. After the expected number of colonies had been reached, about 150 transformants were streaked on LB_(amp)-IPTG plates (0.2 mM IPTG) and incubated overnight at 37° C.

Example 3 Detection of Activity by Filter Assay

The EstC mutants prepared in Example 2 were investigated for their capacity for cleaving substrates with ester bonds. For this, the corresponding plasmids were in each case transformed into the expression strain E. coli BL21 (DE3) (Invitrogen). 10 colonies with the same mutation were tested first with α-naphthyl acetate.

a) Color Assay with Fast Blue B for Cleavage of Naphthol Esters

For this, the colonies and positive controls EstC, EstB and the negative control E. coli BL21 [pMS470Δ8] were streaked in a set pattern on LB-amp-IPTG plates (100 μg/ml ampicillin, 0.2 mM IPTG) and incubated overnight. Then the cell colonies were removed from the agar plate with a sterile paper filter (Whatman, Cat No. 1001-085) and the filter was dried for 10 minutes at 37° C. The bacterial cells were digested for 25 min at room temperature with 500 μl Bug Buster (Novagen) and the filter membranes were then equilibrated for 10 min with 0.02 M potassium phosphate buffer (pH 7.0). For the test with α-naphthyl acetate, 5 ml of buffer (0.05 M Tris-HCl, pH 7.0) was mixed with 100 μl of substrate solution (10 mg/ml α-naphthyl acetate in acetone) and 100 μl of dye solution (10 mg/ml Fast Blue B salt in H₂O) in a glass Petri dish and the filter membranes were impregnated. Formation of a violet-red coloration indicated the activity of the esterase.

b) pH-Shift Assay

The clones most active in each case with the substrate α-naphthyl acetate, were tested for the substrates polymethylacrylate (PMA), polybutylacrylate (PBA) and 2,4-dimethylglutaric acid-dimethyl ester (DG) and 2,4-dimethylglutaric acid-dibutyl ester (DB). For this, as described above, colonies were grown on agar plates and, as described in Example 3a, were transferred onto paper filters.

For preparation of the substrate solution, first a screening solution was prepared, which contained 400 μL phosphate buffer (0.1 M, pH=7.0), 800 μL aqua dest., 500 μL DMSO, 750 μL phenol red (10 g/l) and 400 μL NaOH (0.1 M). For pH-shift assays with DG and/or DB, in each case 200 μl of these substrates were dissolved in each case in 9.5 ml of screening solution and the filter membranes prepared above were impregnated with 1 ml of the substrate solution thus prepared. For pH-shift assays with the substrates PMA and/or PBA, in each case these were pipetted onto dry membranes, the filter membranes prepared above with the lysed cell colonies were impregnated with 1 ml of the screening solution and were laid on the membranes with the substrates. After incubation at RT, the color change from red to yellow, caused by the formation of acid groups after ester cleavage, was determined. The color change could be detected after approx. 20 minutes.

The activity of the clones used is shown in FIG. 5, using the following symbols:

+++: very active ++: active +: weakly active ∘: inactive

Example 4 Preparation of Esterase-Containing Raw Bacterial Lysates

For production of enzyme-containing raw bacterial lysate, first 30 ml of LB medium as preculture, which contained 100 μg/ml ampicillin (hereinafter: LB_(amp)) in a 100 ml Erlenmeyer flask, was inoculated with a bacterial colony and was cultivated overnight on a shaking table at 37° C. and 180 rev/min. Then for the main culture, 500 ml of culture medium [2×TY (10 g/L yeast extract, 16 g/L tryptone, 5 g/L NaCl)] was inoculated with an aliquot of the preculture to an OD₆₀₀ of 0.1 and was cultivated at 30° C., until an OD₆₀₀ of 0.5-0.8 was reached. This was followed by induction of expression with 0.1 mM IPTG and incubation for 16 h at 28° C. The bacterial culture was then centrifuged for 30 min at 4° C. in 1000-ml centrifuge tubes at 4000 rev/min (=3062×g) and the pellets were in each case suspended in 20 ml of 0.1 M phosphate buffer (pH 7). Cell lysis was performed by 5 min of ultrasound treatment, followed by a 1-minute pause, and a further 5 min of ultrasound treatment, using a Branson Sonifier 250, with the duty cycle set at 50% and the power control at level 5. The lysis product obtained was centrifuged for 1 h at 40000 rev/min (=117734×g), sterile-filtered using a membrane with a pore size of 0.2 μm and stored at −20° C. until it was used.

Example 5 Standardization of Enzyme Activity

Raw lysate, prepared as in Example 4, was used as substrate in a photometric assay for cleavage of para-nitrophenylbutyrate (p-NPB) (moreover, a person skilled in the art is able, on the basis of his technical knowledge, to develop assays based on other suitable substrates, for example para-nitrophenylacetate, p-NPA). In this test for determination of esterase activity with para-nitrophenyl esters, 980 μl of buffer (1M Tris buffer, pH 7.0) was mixed with 10 μl of enzyme solution (or dilution of enzyme solution with 1M Tris buffer, pH 7.0) in a cuvette. The reaction was started with 10 μl of substrate solution (400 mM para-nitrophenyl ester in DMSO) and the increase in para-nitrophenol was monitored in a Beckmann UV spectrophotometer at a wavelength of 405 nm.

ε=(para-nitrophenol)11.86 mM⁻¹ cm⁻¹(determined at pH 7.0)

Formula for calculation of activity:

${U\text{/}{ml}} = {\frac{\Delta \; {Abs}\text{/}\min \times V}{ɛ \times 1 \times \nu} \times {dilution}}$

One unit (U) of esterase corresponds to the amount that leads in this assay to conversion of 1 μmol/min.

Example 6 Detection of Enzyme-Catalyzed Cleavage

For differentiation of enzyme-catalyzed substrate cleavage and chemical substrate cleavage, a raw lysate of strain NJ70 (containing a functional mutant of esterase B from Burkholderia gladioli, EstB_NJ70, according to SEQ ID NO:4) was prepared according to Example 4. As substrate solution, 750 μl of PBA solution (CAS No.: 9003-49-0, Sigma Aldrich, 25-30 wt. % in toluene) (equivalent to 1.75 mmol of monomeric ester groups) was added to 35 ml of a master mix (340 ml 0.9% NaCl, 220 ml toluene, 70 ml Emulgen (10% solution in H₂O), pH 7) Emulgen 913, Batch 2265, Kao Chemicals, Osaka Japan, alternatively Tergitol NP-9 from Aldrich can be used) and the pH of the solution was adjusted to 10 with 10 mM NaOH solution. Then 500 μl of raw lysate (equivalent to 1000 units according to the standard established in Example 5) was added and the drop in pH due to acid groups released in the course of cleavage of the ester bonds was compensated by adding 10 mM NaOH. For determination of chemical autolysis, in an independent assay 500 μl of raw lysate with enzyme denatured by boiling for 30 min at 80° C. was added. The results are shown in FIG. 6. After active enzyme is added, because of the acid groups that are released, a large addition of 10 mM NaOH is required for keeping the pH at 10 (curve with rhombus symbols in FIG. 6). In contrast, with additions of denatured enzyme there is only slight ester cleavage by chemical autolysis (curve with triangles in FIG. 6). The sudden increase in consumption of pH correctant (NaOH) immediately after addition of raw lysate with denatured enzyme can be explained by the pH of 7 of the raw lysate.

Example 7 Inhibition of Enzyme-Catalyzed Cleavage by Polyacrylic Acid

The corresponding tests were carried out similarly to Example 6 in aqueous solution, with acid groups being formed by the enzyme-catalyzed cleavage of ester bonds of the substrate used, polybutylacrylate (PBA). These acid groups led to a drop in pH, which was compensated by adding 10 mM NaOH. The amount of NaOH added thus reflects the course of the reaction. All measurements were performed in 35 ml of reaction mixture at pH=9.0 and a temperature of 37° C. 350 units of the esterase EstB_NJ70 (SEQ ID NO:4) and 750 μl of the PBA solution were used, which corresponds to 1.75 mmol of monomeric ester groups. 10 mM NaOH was used as titration solution.

For determination of possible product inhibition, in a parallel assay, at the start of measurement 850 μl of a 20% Sokalan solution was added (Sokalan PA: 15 (polyacrylic acid, Mw 1200, pH 8.0), which is equivalent to 1.74 mmol of monomeric acrylic acid units. As can be seen from the results shown in FIG. 2, the enzymes from Burkholderia gladioli (SEQ ID NO:1; WT in FIG. 7) that were used, and their functional mutants EstB_N27 (SEQ ID NO:3) or EstB_NJ70 (SEQ ID NO:4) were not inhibited or were only minimally inhibited by Sokalan.

Example 8 Dependence of Enzyme-Catalyzed Ester Cleavage on pH

The enzyme-catalyzed ester cleavage was investigated as a function of pH similarly to Example 6. The raw lysates of strain NJ70 (which expresses the functional mutant NJ70, i.e. SEQ ID NO:4) were prepared as described in Example 4 and an amount equivalent to 1000 units was added to substrate solutions, which had been adjusted to various pH values in the range from 5 to 11. To detect possible chemical autohydrolysis at higher pH values (in the range from about pH˜9.0 to pH 11.0), the raw lysates were not added until after 10 min, and in no case was a notable consumption of pH correctant (NaOH) observed prior to addition. It can be seen from the results shown in FIG. 8 that ester cleavage took place in the range from pH 5 to pH 11.

Example 9 Temperature Dependence of Enzyme-Catalyzed Ester Cleavage

The temperature dependence of enzyme-catalyzed ester cleavage was investigated as in Example 6 at a constant pH of 9. As described in Example 4, raw lysates of strain NJ70 were prepared, and were added in an amount equivalent in each case to 1000 units to substrate solutions and were autotitrated at various temperatures in the range from 10° C. to 50° C. As control for chemical autohydrolysis, substrate solution with a pH of 9 was incubated for 10 min at the stated temperature. In the absence of pH change (no consumption of pH correctant), it was concluded that there was no autohydrolysis. It can be seen from the data presented in FIG. 9 that there was a temperature optimum in the range from 20° C. to 40° C., in particular at 30° C.

Example 10 Enzyme Activity of Immobilized Esterase

35 ml of a master mix (340 mL of 0.9% NaCl solution, 220 mL toluene and 70 mL Tergitol (10% in H₂O)), which contained 2 ml of PBA solution (Sigma Aldrich, Mw 99 000, 25-30 wt. % in toluene) (equivalent to 4.66 mmol monomeric ester groups), was adjusted to a pH of 9 and held at a temperature of 37° C. 3.6 ml of raw lysate containing EstB_NJ70 was rotated with 0.5 g of Eupergit C250L (Aldrich) and 30 ml of 0.5 M K₂HPO₄ buffer (pH 9.5) for 48 h at room temperature. Then the suspension was drawn off and the matrix material was washed with 0.1 M Tris buffer (pH 7.0). Then a . . . was

Protein determination according to Bradford showed that 86% of the protein had bound to the support. 50 units of EstB_NJ70, 50 units of EstB_NJ70 immobilized on Eupergit, 50 units of EstB_NJ70 immobilized on Eupergit and denatured, or the corresponding amount of Eupergit without the immobilized enzyme, were added in each case to 35 ml of the aforementioned reaction mixture. The pH was compensated by adding 10 mM NaOH. As shown in FIG. 10, with addition of the two controls (Eupergit without EstB_NJ70 or with denatured EstB_NJ70), slight release of acid groups was observed. In contrast, addition of EstB_NJ70 or immobilized EstB_NJ70 led to a far greater release of acid groups, with the course of the reaction in the case of EstB_NJ70 corresponding to a saturation curve with comparatively high initial reaction rate and a later slowing, whereas the course of the reaction in the case of immobilized EstB_NJ70 had an initially lower rate, but then remained constant during the period of measurement.

Example 11 Ester Cleavage with Short-Chain and Long-Chain Substrates

In each case 35 ml of the reaction mixture stated in Example 10 was adjusted to a pH of 9.0 and a temperature of 37° C. Then in each case 350 units of the esterases stated in FIG. 11 and either short-chain PMA (Sigma Aldrich) with a molecular weight of 30000 (PMAshort in FIG. 11) or long-chain PMA (PMAlong in FIG. 11) with a molecular weight of 40000 were added, equivalent in both cases to 1.75 mmol of monomeric ester groups, and the reaction was carried out either until establishment of equilibrium (FIG. 6) or for the stated period (FIG. 11). The drop in pH due to ester cleavage was compensated by adding 10 mM NaOH, and in FIG. 11, the percentage of hydrolyzed ester groups was calculated from the consumption of NaOH. It can be seen from FIG. 11 that both short-chain and long-chain PMA are cleaved enzymatically. In the case of denatured enzymes (NJ70_den in FIG. 11) the variation in consumption of correctant (NaOH) can be explained by the addition of the respective component to the reaction mixture, as the latter does not have any buffering capacity, so that even minimal amounts of solutions with different pH affect the overall pH.

Reference is made expressly to the disclosure of the publications cited in the present description.

Review of the SEQ ID NOs and Strain Designations Used SEQ ID NO:1

Protein sequence (wild type) of EstB from Burkholderia gladioli

SEQ ID NO:2

Protein sequence (wild type) of EstC from Burkholderia gladioli

SEQ ID NO:3

Mutated protein sequence (internal designation: N27; EstB_N27), for which the following amino acid exchanges were made relative to the wild-type EstB (SEQ ID NO:1): Ser17Leu; Gly132Ser; Glu251Gly; Ala311Val; Glu316Lys

SEQ ID NO:4

Mutated protein sequence (internal designation: NJ70; NJ_(—)70; EstB_NJ70), for which the following amino acid exchanges were made relative to the wild-type EstB (SEQ ID NO:1):

Pro8Leu; Gly132Ser; Trp134Arg; Arg155Cys; Glu251Gly; Ala311Val; Glu316Lys SEQ ID NO:5

Cutinase from Humicola insolens

SEQ ID NO:6

Lipase B from Candida antarctica

SEQ ID NO:7

Esterase from Burkholderia ambifaria (internal designation: AOTF86_(—)9BURK@1)

SEQ ID NO:8

Esterase from Burkholderia cenocepacia (internal designation: Q1BK05_BURCA@1)

SEQ ID NO:9

Esterase from Burkholderia cenocepacia (internal designation: A2W245_(—)9BURK@1)

SEQ ID NO:10

Esterase from Burkholderia cenocepacia (internal designation: AOU6R7_(—)9BURK@1)

SEQ ID NO:11

Esterase from Burkholderia cenocepacia (internal designation: A0B440_BURCH@1)

SEQ ID NO:12

Esterase from Burkholderia cepacia (internal designation: QOB5R9_BURCM@1)

SEQ ID NO:13

Esterase from Burkholderia dolosa (internal designation: A2WH69_(—)9BURK@1)

SEQ ID NO:14

Esterase from Burkholderia mallei (internal designation: ZP_(—)00928253@1)

SEQ ID NO:15

Esterase from Burkholderia mallei (internal designation: Q629M1_BURMA@1)

SEQ ID NO:16

Esterase from Burkholderia mallei (internal designation: A5XMR0_BURMA@1)

SEQ ID NO:17

Esterase from Burkholderia mallei (internal designation: A3 MH33_BURM7@1)

SEQ ID NO:18

Esterase from Burkholderia mallei (internal designation: A1UXM8_BURMS@1)

SEQ ID NO:19

Esterase from Burgholderia multivorans (internal designation: AOUE35_(—)9BURK@1)

SEQ ID NO:20

Esterase from Burkholderia pseudomallei (internal designation: ZP_(—)0131527(3) 1)

SEQ ID NO:21

Esterase from Burkholderia pseudomallei (internal designation: ZP_(—)01209854@1)

SEQ ID NO:22

Esterase from Burkholderia pseudomallei (internal designation: ZP_(—)00893464@1)

SEQ ID NO:23

Esterase from Burkholderia pseudomallei (internal designation: Q3JIF4_BURP1@1)

SEQ ID NO:24

Esterase from Burkholderia pseudomallei (internal designation: A4LP64_BURPS@1)

SEQ ID NO:25

Esterase from Burkholderia pseudomallei (internal designation: A3PA33_BURP0@1)

SEQ ID NO:26

Esterase from Burkholderia pseudomallei (internal designation: A3NPJ8_BURP6@1)

SEQ ID NO:27

Esterase from Burkholderia sp. (internal designation: Q39BM9_BURS3@1)

SEQ ID NO:28

Esterase from Burkholderia thailandensis (internal designation: Q2T2Q0_BURTA@1)

SEQ ID NO:29

Esterase from Burkholderia vietnamensis (internal designation: A4JKI4_BURVG@1)

SEQ ID NO:30

Esterase from Mycobacterium smegmatis (internal designation: A0R6Y0_MYCS2@1)

SEQ ID NO:31

Esterase from Saccharopolyspora erythraea (internal designation: A4FPB3_SACEN@1)

SEQ ID NO:32

Esterase from Saccharopolyspora erythraea (internal designation: A4FDC0_SACEN@1)

SEQ ID NO:33

Esterase from Saccharopolyspora erythraea (internal designation: A4F6M6_SACEN@1)

SEQ ID NO:34

Esterase from Stigmatella aurantiaca (internal designation: Q096X7_STIAU@1)

SEQ ID NO:35

Esterase from Streptomyces ambofaciens (internal designation: A3KIK7_STRAM@1)

SEQ ID NO:36

Esterase from Streptomyces coelicolor (internal designation: NP_(—)630279@1)

SEQ ID NO:37

deletion mutant of EstB_N27 designated as EstB_Short4 (or EstB_N27_Short4), in which the amino acids 317-319 (RGP) from SEQ ID NO:3 (EstB_N27) were removed

SEQ ID NO:38

deletion mutant of EstB_N27 designated as EstB_Short5 (or EstB_N27_Short5), in which the amino acids 248-255 (PLPGGHGA) of SEQ ID NO:3 (EstB_N27) were replaced with the shorter sequence SLGTT

SEQ ID NO:39 to SEQ ID NO:49:

PCR primers according to Example 2

SEQ ID NO:50

Nucleic acid sequence of EstB (according to SEQ ID NO:1)

SEQ ID NO:51

Nucleic acid sequence of EstC (according to SEQ ID NO:2)

SEQ ID NO:52

Nucleic acid sequence of cutinase (according to SEQ ID NO:5)

SEQ ID NO:53

Nucleic acid sequence of lipase B (according to SEQ ID NO:6)

SEQ ID NO:54

Nucleic acid sequence for EstB_N27 (according to SEQ ID NO:3)

SEQ ID NO:55

Nucleic acid sequence for EstB_NJ70 (according to SEQ ID NO:4)

SEQ ID NO:56

Nucleic acid sequence for EstB_N27_Short 4 (according to SEQ ID NO:37)

SEQ ID NO:57

Nucleic acid sequence for EstB_(—N)27_Short 5 (according to SEQ ID NO:38)

SEQ ID NO:58

Hydroxynitrile lyase from Hevea brasiliensis (GenBank No. AAC49184)

SEQ ID NO:59

Hydroxynitrile lyase from Manihot esculenta (SwissProt No. P52705) 

1. A method for the enzyme-catalyzed hydrolysis of polyacrylic acid esters, the method comprising a) preparing a polyacrylic acid ester, b) incubating the polyacrylic acid ester with an enzyme selected from the group consisting of enzymes acting on ester bonds (EC 3.1), whereby at least one ester group of the polyacrylic acid ester is hydrolytically cleaved; and c) optionally, isolating the modified polymer.
 2. The method of claim 1, wherein the enzyme is a carboxylic acid ester hydrolase (EC 3.1.1).
 3. The method of claim 1, wherein the polyacrylic acid ester is a homopolymer or a copolymer.
 4. The method of claim 1, wherein the polyacrylic acid ester is an alternating copolymer, a random copolymer, a gradient copolymer, a block copolymer or a graft copolymer.
 5. The method of claim 1, wherein the modified polymer comprises monomer building blocks of general formula I R¹R²C═CR³—COOR⁴  (I) in which wherein R¹, R² and R³ may be identical or different and are selected from the group consisting of H, a linear C₁-C₂₀ hydrocarbyl residue and a branched C₃-C₂₀ hydrocarbyl residue, and R⁴ is selected from the group consisting of H, a linear C₁-C₂₀ hydrocarbyl residue, a branched C₃-C₂₀ hydrocarbyl residue and a cyclic C₃-C₂₀ hydrocarbyl residue, the hydrocarbyl residue optionally is substituted with one or more identical or different groups selected from hydroxyl, amino, epoxide, thiol groups and halogen atoms, and in the polymer, in at least one monomer building block of formula I, R⁴ is not H.
 6. The method of claim 5, wherein the polyacrylic acid ester contains, additionally to the monomers of formula I, at least one further monomer component different therefrom, in a molar proportion from 0 to 15 mol. %, which is preferably selected from N-vinylformamide, methacrylic acid, methacrylic acid ester, itaconic acid, itaconic acid ester, vinylphosphonic acid, vinylsulfonic acid, vinyl alcohol, N-vinylimidazole, N-vinylformamide, styrene, maleic acid, maleic acid ester, ethylene and/or propylene, and acrylamide and substituted acrylamides, where the substituent is selected from a linear C₁-C₂₀ hydrocarbyl residue, a branched C₃-C₂₀ hydrocarbyl residue and a cyclic C₃-C₂₀ hydrocarbyl residue, the hydrocarbyl residue optionally being substituted with one or more identical or different groups, which are selected from hydroxyl, amino, epoxide, thiol groups and halogen atoms.
 7. The method of claim 1, wherein the enzyme is selected from the group consisting of the esterases of family VIII, type C esterases, the cutinase of SEQ ID NO:5 and a cutinase derived therefrom, and the triacylglycerol lipase of SEQ ID NO:6 and a triacylglycerol lipase derived therefrom.
 8. The method of claim 1, wherein the enzyme is selected from the group consisting of the proteins of SEQ ID NO:1 (esterase B from Burkholderia gladioli), SEQ ID NO:2 (esterase C from Burkholderia gladioli) and functional mutants derived therefrom.
 9. The method of claim 8, wherein the enzyme is a mutant of the esterase of SEQ ID NO:1 or SEQ ID NO:2, and wherein at least one of the activity with respect to the hydrolysis of polyacrylic acid esters is comparable or increased relative to the activity of the esterase of SEQ ID NO:1 or SEQ ID NO:2, the stability is increased relative to the stability of the esterases of SEQ ID NO:1 or SEQ ID NO:2.
 10. The method of claim 9, wherein the mutant shows increased hydrolytic activity against at least one of polyacrylic acid methyl esters or polyacrylic acid butyl esters compared to the hydrolytic activity of the esterases of SEQ ID NO:1 or SEQ ID NO:2.
 11. The method of claim 9, wherein (a) the mutant of the esterase of SEQ ID NO:1 has a mutation in one or more of the amino acid residues Ser17, Gly132, Trp134, Arg155, Glu251, Ala311 and Glu316; or (b) the mutant of the esterase of SEQ ID NO:2 has a mutation in one or more of the amino acid residues Phe138, Val150, Leu160, Thr188 and Leu193.
 12. The method of claim 9, wherein the mutant is derived from SEQ ID NO:1 and (a) comprises at least one of the mutations Ser17Leu, Gly132Ser, Glu251Gly, Ala311Val and Glu316Lys; or (b) comprises at least one of the mutations Pro8Leu, Gly132Ser, Trp134Arg, Arg155Cys, Glu251Gly, Ala311Val and Glu316Lys.
 13. The method of claim 9, wherein the mutant is derived from SEQ ID NO:2 and comprises one of the following mutations or combinations of mutations: (a) Phe138Ala (b) Phe138Ala, Thr188Ser (c) Phe138Ala, Leu160Ala, Thr188Ser (d) Leu193Ala (e) Leu193Ala, Phe138Ala, Thr188Ser, Val150Ala (f) Leu193Ala, Phe138Ala, Thr188Ser (g) Leu193Ala, Phe138Ala, Thr188Ser, Leu160Ala, Val150Ala (h) Val150Ala (i) Val150Ala, Thr188Ser (j) Leu193Ala, Phe138Val (k) Leu193Ala, Phe138Val, Thr188Ser, Val150Ala (l) Leu193Ala, Thr188Ser (m) Leu193Ala, Phe138Val, Thr188Ser (n) Leu193Ala, Phe138Val, Thr188Ser, Leu160Ala (o) Phe138Val, Val150Ala, Thr188Ser (p) Phe138Val (q) Phe138Val, Thr188Ser
 14. The method of claim 7, wherein the mutant is a deletion mutant of an esterase of family VIII or of a type C esterase.
 15. The method of claim 14, wherein the deletion mutant has at least one loop shortening.
 16. The method of claim 15, wherein the deletion mutant has an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO:37 and SEQ ID NO:38.
 17. (canceled)
 18. A nucleic acid, which a) codes for the esterase mutant of claim 26, or b) represents a nucleic acid complementary to a), or c) hybridizes to a nucleic acid according to a) or b) under stringent conditions, has a sequence identity of at least 80% and codes for a mutant of an esterase of family VIII or for a type C esterase mutant, which hydrolyzes polyacrylic acid esters.
 19. A vector comprising the nucleic acid of claim
 18. 20. The vector of claim 19, wherein the nucleic acid is linked operatively to a promoter.
 21. A microorganism comprising the vector of claim 19, wherein the nucleic acid optionally is linked operatively to a promoter.
 22. A method of producing the esterase of claim 26, the method comprising a) cultivating a host organism capable of expressing an esterase of claim 26; b) optionally, inducing expression of the esterase is induced, and c) optionally, isolating the esterase from at least one of the host organism or the culture medium.
 23. (canceled)
 24. A polymeric reaction product obtained by the method of claim
 1. 25. The method of claim 2, wherein the carboxylic acid ester hydrolase (EC 3.1.1) is selected from the group consisting of carboxyl esterases (E.C. 3.1.1.1), triacylglycerol lipases (EC 3.1.1.3) and cutinases (3.1.1.74).
 26. A functional esterase mutant a) selected from the protein of SEQ ID NO:1 (esterase B from Burkholderia gladioli), SEQ ID NO:2 (esterase C from Burkholderia gladioli) or functional mutants derived therefrom; b) that is the esterase of SEQ ID NO:1 or SEQ ID NO:2, and wherein at least one of the activity with respect to the hydrolysis of polyacrylic acid esters is comparable or increased relative to the activity of the esterase of SEQ ID NO:1 or SEQ ID NO:2, the stability is increased relative to the stability of the esterases of SEQ ID NO:1 or SEQ ID NO:2; c) that shows increased hydrolytic activity against at least one of polyacrylic acid methyl esters or polyacrylic acid butyl compared to the hydrolytic activity of the esterases of SEQ ID NO:1 or SEQ ID NO:2; d) that is the esterase of SEQ ID NO:1 having a mutation in one or more of the amino acid residues Ser17, Gly132, Trp134, Arg155, Glu251, Ala311 and Glu316; or the esterase of SEQ ID NO:2 has a mutation in one or more of the amino acid residues Phe138, Val150, Leu160, Thr188 and Leu193; e) that is derived from SEQ ID NO:1 and comprises at least one of the mutations Ser17Leu, Gly132Ser, Glu251Gly, Ala311Val and Glu316Lys; or comprises at least one of the mutations Pro8Leu, Gly132Ser, Trp134Arg, Arg155Cys, Glu251Gly, Ala311Val and Glu316Lys; f) that is derived from SEQ ID NO:2 and comprises one of the following mutations or combinations of mutations: (a) Phe138Ala; (b) Phe138Ala, Thr188Ser; (c) Phe138Ala, Leu160Ala, Thr188Ser; (d) Leu193Ala; (e) Leu193Ala, Phe138Ala, Thr188Ser, Val150Ala; (f) Leu193Ala, Phe138Ala, Thr188Ser; (g) Leu193Ala, Phe138Ala, Thr188Ser, Leu160Ala, Val150Ala; (h) Val150Ala; (i) Val150Ala, Thr188Ser; (j) Leu193Ala, Phe138Val; (k) Leu193Ala, Phe138Val, Thr188Ser, Val150A1a; (l) Leu193Ala, Thr188Ser; (m) Leu193Ala, Phe138Val, Thr188Ser; (n) Leu193Ala, Phe138Val, Thr188Ser, Leu160Ala; (o) Phe138Val, Val150Ala, Thr188Ser; (p) Phe138Val; or (q) Phe138Val, Thr188Ser; g) that is a deletion mutant of an esterase of family VIII or of a type C esterase; h) that is a deletion mutant of an esterase of family VIII or of a type C esterase and has at least one loop shortening; or i) that has an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO:37 and SEQ ID NO:38. 